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To:      AIChE National Review Committee 
From:  Group 1737 
Subject:   Completion of Neural Stem Cell Manufacturing Facility 
 
To whom it may concern: 
 
Group 1737 was organized in an attempt to design a manufacturing facility that produces neural 
stem cells.  We are pleased to announce the completion of the design along with a detailed 
economic and safety analysis.  The group recommends pursuing the construction of the 
manufacturing facility with plans to expand internationally when the economic opportunity is 
present.   
We are looking forward to the review from your committee. With this transmittal, the group 
gives the committee permission for public review on the facility.  The quality input will be used 
as a tool for improving the facility as the group looks to move into detailed design.  We look 
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 Over the past ten years, advances in stem cell therapy have progressed from low yield 
treatments on small organisms, to effective, targeted treatments on humans.  One of the largest 
markets for stem cell therapy is treatment of bodily injury, particularly in the nervous system.  
Research has shown that induced pluripotent stem cells can expand and differentiate into neural 
stem cells, which has been clinically shown to relieve pain caused by spinal cord injuries.16 
Currently, over 250,000 Americans suffer from spinal cord injuries, with a 5% increase predicted 
over the next five years.  Stem cell therapy is a rapidly developing field to provide treatment of 
these injuries, and with the technology available, a facility can be design to produce enough 
neural stem cells to treat the entire market.   
Specifically, induced pluripotent stem cells have shown to grow rapidly with relatively 
high viability in vitro.  By selectively differentiating induced pluripotent stem cells into neural 
stem cells, a large amount of neural stem cells can be provided to victims of spinal cord injury. 16    
The facility outlined in this report is designed to take a batch of 100,000 induced pluripotent 
stem cells and create enough neural stem cells to treat the predicted American population over 
the next five years.  The total amount of neural stem cells needed to treat the entire market is 
approximately 1.2 trillion cells per year.  Batch processes, especially pharmaceutical processes, 
have relatively low service factors.  A service factor of 0.75 was determine in order to account 
for the significant down time associated with batch processes because sterilization is key to 
maintaining the integrity of the facility and product.   
Economically, the viability of the project has been evaluated over a 5 year time period 
with a minimum rate of return of 50%. It is very likely that international expansion will present 
an economic opportunity in a relatively short time frame. To account for potential expansion, the 
facility has the ability to incorporate overseas markets when the opportunity arises.  It is 
recommended that the company moves forward with detailed design of the facility immediately 














Stem cell therapy is at the frontier of modern treatment methods. Research has shown 
that the efficiency of stem cell cultures has increased exponentially over the last five years; 
however, this advance is met with an increasing market size.  Stem cell treatment has been 
validated on a small scale, but there are currently no large scale treatment options are available in 
the United States due to restrictions by the FDA.27 On the other hand, other countries that 
implement stem cell therapy have produced promising results.  Spinal cord injuries that are 
treated outside of the United States typically consist of a series of 12-16 injections, with each 
injection consisting of around three million stem cells19. The total number of people affected by 
spinal cord injuries in the United States over the next five years is predicted to be 310,000.  In 
order to make enough stem cells to treat the entirety of the affected population in the United 
States, a facility needs to be able to have a high viability of stem cells, with extreme precision 
and efficiency within the process.  Furthermore, the facility needs to have a high throughput in 
order to meet the market demand, but costs need to be minimized to ensure the economic 
viability of the project.  Overall, recent stem cell research has shown potential for production of 
high throughput processes that allow the industry to reach a larger market. However, no current 
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Process Flow Diagram: 
In the Process Flow Diagrams seen across the next few pages, the volumes given are the 
total volume for one batch.  In particular, the media is changed more than once per batch; 
however, the replaced media is not of equivalent volume to the original media.  Since cell 
concentration must be maintained within a certain range, a larger volume of replacement media 
is needed than the original volume due to an increased number of cells.  Therefore, it is more 
applicable to display the volume per batch instead of the volume added when materials need to 
be replaced.   The process is illustrated over three drawings for clarity and simplicity.  
 
 











































































































Figure 1-PFD of Neural Stem Cell Production Facility  
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Figure 2-PFD of Neural Stem Cell Production Facility 
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Figure 3-PFD of Neural Stem Cell Production Facility  
 
 




Table 1-Stream Summary Table for Neural Stem Cell Production Facility
Stream number 1 2 3 4 5 6 7 8 9 10 11 12 13
Phase Solid/Liquid Liquid Gas Liquid Solid/Liquid Solid Solid/Liquid Solid/Liquid Gas Liquid Solid/Liquid Solid/Liquid Liquid
Pressure (psig) 0.00 0.00 15.00 0.00 0.00 0.00 0.00 0.00 15.00 0.00 0.00 0.00 0.00
Temperature (°C) 37.00 37.00 20.00 37.00 37.00 37.00 37.00 37.00 20.00 37.00 37.00 37.00 37.00
Heat Capacity (J/gC) 3.45 4.3 1.0005 4.3 4.3 3.45 4.3 3.45 1.0005 4.3 4.3 3.45 4.3
Actual Density (kg/m3) 1125.00 1100.00 1.225 1100.00 1100.00 1125.00 1100.00 1125.00 1.225 1100.00 1100.00 1125.00 1100.00
Total Volumetric Flow Rate (mL/batch) - - - - - - - - - - - - -
iPSCs (mL) 6.30E-04 - - - 7.56E-03 7.56E-03 9.08E-02 9.08E-02 - - 1.09E+00 1.09 -
Expansion Media (mL) - 3.20 - 24.00 1.20 - 12.00 - - 288.00 144.00 - 3456
Air (mL/min) - - 0.31 - - - - - 0.14 - - - -
Differentiation Media (mL) - - - - - - - - - - - - -
NSCs (mL) - - - - - - - - - - - - -
Stream number 14 15 16 17 18 19 20 21 22 23 24 25 26
Phase Gas Liquid Solid/Liquid Solid/Liquid Liquid Liquid Solid/Liquid Liquid Gas Solids/Liquids Gas Solid/Liquid Liquid
Pressure (psig) 15.00 0.00 0.00 0.00 0.00 0.00 0.00 15.00 28.00 0.00 25.90 0.00 0.00
Temperature (°C) 20.00 37.00 37.00 37.00 37.00 37.00 37.00 20.00 134.00 37.00 127.00 37.00 37.00
Heat Capacity (J/gC) 1.0005 4.3 4.3 4.3 4.3 4.3 3.45 4.3 2.19 4.299 2.19 3.45 4.3
Actual Density (kg/m3) 1.23 1100.00 1100.00 1100.00 1100.00 1100.00 1125.000 1100.00 1.58 1100.00 1.58 1125.00 1100.00
Total Volumetric Flow Rate (mL/batch) - - - - - - - - - - - - -
iPSCs (mL) - - 13.05 13.05 - - 13.4 - - 19.80 - 19.80 -
Expansion Media (mL) - 315.2 1730 1730 1730 2.07E+04 - - - 2.07E+04 - - 2.07E+04
Air (mL/min) 173.00 - - - - - - 2.07E+03 - - - - -
Differentiation Media (mL) - - - - - - - - - - - - -
NSCs (mL) - - - - - - - - - - - - -
Steam (L) - - - - - - - - 41400 - 20760 - -
Stream number 27 28 29 30 31 32 33 34 35 36 37 38 39
Phase Liquid Solid Gas Gas Solid/Liquid Solid/Liquid Solid/Liquid Liquid Liquid Gas Solid/Liquid Liquid Liquid
Pressure (psig) 0.00 0.00 15.00 28.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.00 15.00
Temperature (°C) 37.00 37.00 20.00 134.00 37.00 25.00 25.00 25.00 25.00 25.00 -80.00 37.00 37.00
Heat Capacity (J/gC) 4.3 3.45 1.0005 2.19 4.28 4.28 4.28 4.184 1.96 4.184 4.184 4.184 4.184
Actual Density (kg/m3) 1100.00 1125.00 1.23 1.58 1100.000 1100.00 1100.00 1050.00 1050.00 1050.00 1050.00 1050.00 1050.00
Total Volumetric Flow Rate (mL/batch) - - - - - - - - - - - - -
iPSCs (mL) - 1.98E+01 - - - - - - - - - - -
Expansion Media (mL) 1.84E+05 - - - - - - - - - - - -
Air (mL/min) - - 5230 - - - - - - - - - -
Differentiation Media (mL) - - - - 52330 52331 - - - - -
NSCs (mL) - - - - 396 396 396 - - - 396 - -
Water-(Steam/Water for Injection) (L) - - - 52330 - - 20.9 20.9 - - 20.9 1.86 L/hr 4.87 L/hr
Dimethylsulfoxide (L) - - - - - - 2.09 - 2.09 - 2.09 - -
Formaldehyde (L) - - - - - - - - - 39.25 - - -
Stream Summary Table - Expansion and Differentiation of Induced Pluripotent Stem Cells to Neural Stem Cells
Stream Summary Table - Expansion and Differentiation of Induced Pluripotent Stem Cells to Neural Stem Cells
Stream Summary Table - Expansion and Differentiation of Induced Pluripotent Stem Cells to Neural Stem Cells
 
 




 To verify the system meets constraints material and energy balances were performed. The 
validity was determined by stating that what enters a unit must be equals what comes out.  In 
order to perform and accurate material balance, cell and media densities need to be 
approximated. The material balances were done on a mass basis and densities were assumed to 
be uniform. The values for the density of media, stem cells, and air are 1100 kg/m3, 1125 kg/m3, 
and 0.0012 kg/m3, respectively8. If the difference between mass that enters and mass that exits is 
approximately zero then the system was considered balanced.  Each expansion vessel as well as 
the differentiation reactor were balanced.  A summary is seen in Table 1 and in the Appendix for 
all of the units.  
CP-101 











Table 2-Sample Material Balance Calculation 
  
 The first expansion material balance was performed as follows. There are 7.1 x 10-4g of 
cells entering the system and 1.1g of fresh media entering. 1.10071g of material leaves after 86 
hours. This yields 1.0 x 10-6 as the difference between what comes in and what exits. This is 
close enough to zero; therefore, this system is balanced. 
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  Similarly, the second expansion has 8.51 x 10-3g of cells entering with 13.2 g of fresh 
media. 13.2021 g of spent media and expanded cells leaves the system after 84 hours. The 
difference between in and out was found to be 6.4 x 10-3. This confirms the system is balanced.
 The third expansion has 0.102g of cells entering. There is 158.4 g of media entering as 
well. With this system, air is fed to this expander and the total oxygen consumed is 0.867g per 
batch. The amount of material out from this batch is 159.3g. The difference between in and out 
of the system is 0.0721. This is small enough to consider the system balanced  
 Moreover, the fourth expansion has 1.23g of cells entering. The media entering is 1901g 
and the oxygen amount entering is 0.867g. The final mass of the leaving mixture is 1901.95g. 
The difference in material in and out is 0.95g. In comparison to the overall magnitude of the feed 
streams this difference is small enough to be considered zero. This is the last expansion carried 
out in the laminar flow cabinet.  
 Lastly, the fifth expansion is carried out in a 40L bioreactor with air sparged through the 
media. The mass of cells entering is 14.68g and the mass of media added is 22,814g. The amount 
of oxygen added is 2.19g. This make the overall difference 0.92g. This is low enough to qualify 
as balanced.  
 The differentiation is the last step in the process. The amount of cells entering is 22.4g. 
The amount of media charged is 57,560g. The amount of oxygen delivered is 63.2g. The final 
amount out of the system is 57,607g. The difference then from in and out is 42.11g. This is a 
little large compared to the other units but compared to the overall system this is within 
acceptable range. A possible explanation of this is the lack of information of growth rates and 
substrate consumption rate of the cells during differentiation. Overall though this unit was 
considered balanced taking into account the uncertainty of the kinetic data.
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Process Description:  
Stem cell culturing is a delicate process and caution must be used throughout the process.  
The process begins with a batch of 100,000 induced pluripotent stem cells stored in a 1mL 
plastic vial in the vapor phase of a liquid nitrogen tank.  Specifically, a temperature indicator and 
low temperature alarm are set to notify operators of a significant decrease in the temperature of 
the tank.  The stem cells need to be kept at cryogenic conditions until the facility is ready to 
operate in order to properly preserve the raw materials.  Premature thawing of the cells 
significantly reduces the overall production17.  Once the facility is ready to begin a batch, the 
induced pluripotent stem cells are transferred from cryogenic storage to a thaw bath for two 
minutes to fluidize the cells.  Water at 40oC is used to thaw the cells at an appropriate rate.  After 
two minutes, the stem cells are then transferred by an operator to a 35mm square culture plate.   
 For all expansion chambers, the expansion media chosen is Essential 8 by Gibco. For the 
first expansion, 1.6mL is used each change in conjunction with the cell culture.  The media in the 
culture is changed every three days and the cells stay in the culture plate for 85 hours.  The cells 
are separated from the media via centrifuge and transferred to a 25mL T-Flask with fresh media 
for 85 hours.  The cell culture goes through five expansion chambers in total, each with the same 
residence time. The size of the final three expansion chambers are 150mL, 2L, and 40L, 
respectively.  At the end of the expansion phase, the number of cells is expected to grow from 
100,000 to around 3.1 billion over the course of 15 days.  In order to detach the cell aggregates, 
trypsin is added before the cells are removed. Moreover, all expansion chambers are kept at 37oC 
via electrical heating by a hot plate.  Before transferring the process into a larger expansion 
chamber, the process is concentrated and water for injection is used to fluidize the cells to allow 
for transportation.  After the 5th expansion chamber, the cells are sent to a centrifuge to isolate 
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the stem cells from the media where they are then fed to a bioreactor.  For each expansion 
chamber, an oxygen consumption rate of 15.4 pmol/hr is used to determine the amount of 
oxygen needed to be supplied for each batch.  Similarly, a media consumption rate of 8.51 
pmol/hr is used to determine how often the media needs to be changed in the permanent 
expansion chamber26.   
In order to determine how long to keep the induced pluripotent stem cells, solver was 
used to maximize the operating time throughout the year by changing the total residence time of 
the cells in the expansion phase by varying the number of batches per year with the constraint of 
meeting the need for the market.  The result is the ideal residence time of the cells in the 
expansion phase.  However, nothing regarding the number of chambers, size, or media volume is 
included.  Based on research, the media needs to be changed every other day to prevent unviable 
conditions of the cells.  Cell cultures have shown significant a significant drop off in viability at 
concentrations over 1.2 million cells/mL because cells will compete against each other for 
nutrients17.  To prevent this, cells are transferred to a larger expansion chamber with a higher 
volume of media to dilute the concentration of the cells.  To produce the number of cells that 
need to be produced for each batch and maintain the appropriate concentrations, five expansion 
chambers are used with increasing size to maximize the efficiency of the process.  Also, multiple 
articles have shown the doubling time of induced pluripotent stem cells to be around 24 hours.  
This produces a logarithmic relationship between growth factor and residence time.  A graph of 
this relationship can be seen in Figure 4. 
 
 




Figure 4-Graph of Residence Time versus Growth Factor 
 
 Additionally, number of cells versus residence time has an exponential relationship, 
which is consistent with standard cell growth.  Similarly, this relationship is depicted graphically 
in Figure 5. Approximately three billion cells are sent to the reactor, which after differentiation 
produces around 58 billion neural stem cells per batch. This factor is specific to the neural cell 
media specification for growth factors. To meet market demand, 19 batches of 58 billion induced 
pluripotent stem cells are required.   
 
 




Figure 5-Graph of Number of Cells versus Residence Time 
   
 As stated previously, centrifuges are used after each expansion step to separate stem cells 
from media.  For this process, centrifuges that handle very small volumes are placed in a vial and 
are separated in a closed system while large volumes are separated using an open flow system.  
The first three expansion chambers all use the same centrifuge because it can handle the small 
range of volumes.  However, the other two centrifuges are open systems. For open system 
centrifuges, fluid is sent through the system, where stem cells stick to the wall, and then removed 
and transferred to the next unit.  Each open system centrifuge is constructed from stainless steel 
to prevent contamination of the cells. 
 The bioreactor has a 200L reactor volume and the liquid level in the reactor is expected to 
range from 22 liters to 53 liters over the course of seven days.  The bioreactor needs to be able to 
handle one trillion neural stem cells each year to meet market demands.  Neural induction media 
is added to the process to initiate differentiation to neural stem cells. The media is changed every 
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other day to maintain the proper process conditions in the bioreactor. A low shear agitator is used 
to maintain a well-mixed composition to ensure maximum yield.  Low shear is critical to ensure 
that the stem cells are not damaged during the differentiation process.  Furthermore, three 
process variable are critical to control in the reactor: pH, temperature, and oxygen 
concentration5.  A change in pH is directly associated with consumption of media.  As the 
nutrients in the media are consumed, waste is produced and the pH will deviate from ideal 
conditions.  Once the pH reaches unacceptable conditions, the media is changed to minimize cell 
death22.  Controls systems are installed to notify operators when the media needs to be changed 
to prevent undesirable conditions.  Likewise, temperature is controlled by pulling a slip stream 
off of the boiler to provide hot water to maintain a temperature of 37oC inside the vessel17.  Since 
the bioreactor is insulated, a minimal amount of heat is lost from the system.  However, an 
automated temperature controller is necessary due to the economic consequences; the hot water 
feed is essential to maintaining the viability of the cells and needs to be controlled as precisely as 
possible.  Lastly, the oxygen concentration is critical to the viability of the stem cells.  Mitosis 
requires glucose and amino acids that the media provides as well as oxygen from a sparger to 
maximize the efficiency of cell division.  Since oxygen concentration of the process is vital, an 
automated controls system is added to more precisely maintain the ideal operating conditions.  
Oxygen concentrations are set at 20% through a flow controlled gas sparger.  After seven days in 
the bioreactor, the cells are sent to an inactivation chamber, where 37% gaseous formaldehyde is 
added at 1.31 liters per second for two hours.  This step removes any viruses in the process, but 
does not harm the neural stem cells10.  Gaseous formaldehyde targets the protein coat of the virus 
to inactivate it.   
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In order to separate the differentiated stem cells from the undifferentiated stems cells, a 
magnetic automated cell separator is used to sort the cells.  Antigens with metal attached are 
injected into the process that bond to the neural stem cells and leaves the undifferentiated cells 
untouched.  The batch stays in the separator for two hours to allow for complete separation.  
After two hours, the undifferentiated stem cells pass through the unit and the neural stem cells 
are removed from the separator by using water for injection.  The cells are concentrated down to 
three million cells per milliliter using water for injection.  In order to protect the cells, DMSO is 
added as a cryopreservative and the finished product is sent to cryogenic storage that is kept at -
148oC using liquid nitrogen15.  Again, temperature control is critical to the viability of the 
product.  The neural stem cells are kept in storage until it is shipped to the formulation group to 
prepare the product for packaging.    
 
Energy Balance and Utility Requirements:  
 A large amount of operating costs each year is spent on energy consumption in the form 
of heating and cooling. Balances on all of the units was necessary to confirm the validity of the 
design calculations. The balance was performed in similar fashion to the mass balance by finding 
the energy into the unit and subtracting the energy out of the system and adding the energy either 
transferred into or out of the system. This sum should add to be zero if the system is truly in 
balance. Due to uncontrollable losses, however, none of the energy balance summed to exactly 
zero. The physical data of the system can be seen below in Table 3. These heat capacity values 
were estimated based on medium properties as well as cell properties. The heat of reaction for 
the cell growth and differentiation were determined to be negligible due to the low amount of 
heat needed for temperature control as well as the heat transferred in the laminar flow cabinet as 
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the cabinet has such a controlled environment. All energy balances are found in the Appendix. A 
sample is located at the end of this section.  
For Streams 1, 2, and 5 the energy was calculated by Equation 1 below. Where Cp is the 
heat capacity above and T is the temperature of the stream entering.  
ℎ = 𝑚𝐶𝑝𝑇                                                                     (1) 
Where: 
h = enthalpy of the material (J) 
m = Mass of the Material (g) 
Cp = Heat Capcity of the Material (J/gC) 
T = Temperature of the Material (C) 
The energy into the system was calculated as 0.062 Joules (J) for Stream 1 using 
Equation 1. For Stream 2 the amount of heat entering the first expansion is calculated as 118.25 
J. The heat exiting the system in Stream 5 then is calculated as 118.33 J. Finding the difference 
then becomes -0.0148 J: small enough to be considered balanced. 
For TF-100, the same process was applied by using Equation 1 across all of the streams. 
For Stream 6 the amount of energy entering is found to be 0.738 J. For Stream 4 the energy is 
2100.1 J for the media entering. For the exiting mixture in Stream 7, the heat is 2100.46 J. This 
leaves the difference of the in and out as 0.40 J with neglecting heat transfer from the box. The 
value of the difference is low enough to be accepted.  
The first stirred flask, SF-100, has 8.857 J entering with the cells, 25201.4 J with the 
fresh media. This is the first expansion to require air so the energy entering with Stream 9 is 21.8 
J. The final mixture exits with 25226 J of energy. This leaves a difference between energy in and 
out at 5.8 J. This is small enough when compared to the overall amount of energy in the system. 
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This step is still contained in a laminar flow box so the energy transferred by the system is 
considered negligible.  
 The second stirred flask, SF-101, the cells bring in 106.7 J in Stream 12. The media is 
Stream 13 brings in 302,417 J. The air brings in 21.7 J in stream 14. The exit mixture has an 
energy amount of 302,529 J. These values give a balance of 16.4 J. This is a close enough value 
in comparison with the stream values to justify a balance closing.  
 The fifth expansion chamber is the first vessel to be outside of a laminar flow cabinet. 
This required a jacketed to maintain the temperature in the vessel. To calculate the amount of 
heat needed to maintain the internal temperature, the vessel dimensions of length 0.587 m and 
diameter 0.147 m were found by using Excel Solver to find the L and D that satisfy an L/D ratio 
of four.25 The heat transfer area was estimated as the surface area of a cylinder with the 
dimensions given above. This gives a surface area of 0.271 m2 for the inner surface the outer was 
found by adding a half inch of insulation to the outer thickness of the vessel. The outer surface 
area was found to be 0.277 m2. The heat transfer rate could then be found by using the resistance 
method detailed in Perry’s Chemical Engineers Handbook24. The heat transfer rate to the 
environment was found to be 1.19 Watts or 4.056 BTU/hr. This amount although small is non-
negligible. Using this rate and a hot water stream the flow rate of water needed to keep the 
internal temperature was calculated to be 1.85 kg/hr. This ensures there is no significant 
temperature change in the reactor. To perform the energy balance, Stream 19, the fresh media 
feed was found to carry 3.63 MJ. The cells carry 1,880 J of energy and the air has 55 J of energy. 
The heating from the water over the cycle introduces 6,260 J of energy. The heat loss to the 
environment is 6,260 J The final amount of energy out of the system is found to be 3.63 MJ. This 
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gives a difference of 1,092 J. This is close enough to zero given the magnitude of the other 
streams.  
 The differentiator was sized in a similar manner to the final expander with an L/D of 4 
and a final vessel size of 108 liters. The heat loss with a half inch of insulation was found to be   
-3.1 Watts. This means that water at a flow rate of 4.85 kg/hr at 1 degree temperature drop. This 
gives a total amount of heat needed to be transferred at 1.87 MJ. The cells bring in 19.4 kJ from 
Stream 28. The media brings 9.1583 MJ in stream 27 and the air brings in 1,590 J with Stream 
29. The final amount of heat coming out of the system is found to be 9.16 MJ. This gives a total 
difference of 1,940 J. This is low enough when compared to the stream magnitudes.  
 The final unit is the refrigeration unit for final storage. This unit needs a large amount of 
energy due to the large temperature drop the cells require to remain viable long term. The energy 
for the system was found using Equation 2 below.  
𝑄 = 𝑚𝐶𝑝(𝑇 − 𝑇𝑓) + 𝑚𝜆 + 𝑚𝐶𝑝𝑠(𝑇 − 𝑇𝑓𝑖𝑛𝑎𝑙)                                     (2) 
Where: 
 Q = heat transfer needed  
m = total mass being chilled (kg) 
T = initial temperature of mixture (oC) 
𝑇𝑓 = fusion temperature (
oC) 
𝜆 = heat of fusion of mixture (J) 
𝐶𝑝𝑠 = heat capacity of the solid mixture (J/kg
 oC)  
𝑇𝑓𝑖𝑛𝑎𝑙 = final temperature of the mixture (
oC) 
Most of the energy needed to chill comes from the freezing process as would be expected 
from any phase change. The constant values are seen below in Table 4. Using Equation 2 with 
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the constants below the energy needing to be transferred was found to be -12,867 kJ. This is 
handled by Asymptotes VIA freeze QUAD system. The cycle time for a batch was found to be 
117 minutes with a maximum cooling rate of 1 C/min.  
 
Table 4-Refrigeration Constants 
 
 
Table 5-Example Energy Balance 
 Once the energy balances confirmed the validity of the equipment design, utility costing 
was performed. The overall utility costs were relatively low due the process consisting of batch 
reactors with residence times under three minutes. Additionally, much of the equipment did not 
require utilities as the glucose within the cellular media provided the energy for the reactions to 
occur as opposed to heat or high pressures. It is important to note that the process is a batch 
process so the cost of utilities per year is determined by calculating the utility cost per batch and 
multiplying the cost per batch by the total number of batches.  The majority of units which 
Mass In (g) 25645
Cp (J/gC) 4.545
Heat of Fusion (J/g) 333.55
Cps (J/gC) 1.4
Initial Temperature (C) 25
Freezing Temperature (C) 0
Final Temperature (C) -80
Energy Required (kJ) 14340
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required utility input were support systems for the process itself, such as the boiler and laminar 
flow cabinets.  
 The utility costs for predesigned equipment was determined by converting the set voltage 
and electrical currents to power in kilowatts and using the provided costing information of $0.05 
per kW-hr. This method was applied to R-300, the laminar flow cabinet, the air filtration 
systems, and the centrifuges: C-100, C-200, C-300. A sample of this calculation can be seen 
below. All other calculations of this method can be found in the Appendix.  
Purifier Utilities 
Volts V 230 
Amps A 5.4 
Power kW 1.242 
Energy Used per Batch 
kW-hr 10335.92 
Price of Energy Per 
Batch $/kW-hr 0.05 
Price to Run $/Year 9818.59 
 
Table 6-Purchased Equipment Utility Costs 
 For all other units, hand calculations using data and engineering heuristics were used to 
approximate energy consumption. One such unit this for which this method was used is the 
boiler unit. Both the costs of electricity to heat the coils and the boiler feed water were calculated 
using by hand calculation found in Analysis, Synthesis, and Design of Chemical Processes.25 An 
example of the costing process can be seen below equations for the sample calculation can be 
found in the Appendix.   
 
Operational Costing 
Boiler Feed Water $/kg 0.00245 
Electricity $/kW-hr 0.05 
Boiler Feed Water $ 0.010995 
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Electricity $ 586.8408 
Total $ 586.8518 
Total/year  11150.18 
 
Table 7-Boiler Utility Costs 
 Water proved to be an important utility in the process because it is needed for 
sterilization in between batches.21 For both the final expansion chamber, BR-200, and the 
differentiator, BR-300, water is needed to heat the jacketed reactors to isothermal conditions. 
Instead of installing a heat exchanger to heat the water before feeding it to the reactor jacket, 
excess boiler feed water is fed to the reactor. Boiler feed water is used because the low cost of 
the utility makes slightly oversizing the boiler more economic than purchasing two new heat 
exchangers.25 Additionally, water for injection for the final product vials is needed to prepare the 
stem cells for injection into a patient. The total weight of the water for injection need was 
calculated by determining the necessary concentration for therapy in the vials with the cells and 
replacing the media with water for injection.20 Finally, boiler feed water was also used in the 
warm water bath to thaw the frozen iPSCs after cryostorage. Boiler feed water was selected to 
warm the cells due to the low cost and because the boiler feed water is treated, making it less 
harsh on the cell vials. An example calculation of the energy calculations for the warm water 
bath can be seen in Table 8.  
 
 












Table 8- Energy Transfer for Thawing of Stem Cells 
 
Equipment List and Unit Descriptions: 
Boiler:  
To prevent contamination, the process equipment is sterilized between each batch. Due to 
its low operating cost, steam-in-place was chosen as the method of sterilization. A boiler is used 
to generate the necessary 132 ºC saturated steam for steam-in sterilization. 132 ºC saturated 
steam was chosen for sterilization due to its common use in CDC sterilization techniques.21 The 
boiler must generate enough steam to contact the all of the surface area of the process vessels 
with steam for three minutes. The total volume of all the process vessels is 0.272 m3; however, 
the boiler was sized to produce ten times the volume of steam necessary to both meet industry 
standards and ensure enough steam is produced to fill the process vessels for the full 3 minute 
sterilization time.21 In order to generate 2.72 m3 of steam, 4.30 kg of boiler feed water is fed to 
the boiler for each steam-in process. The boiler has a duty of 62 kW to convert the boiler feed 
water to saturated steam. Due to the relatively small duty of the boiler and lack of corrosive or 
caustic materials, plain carbon steel was used as the MOC to avoid unnecessary cost.  After use, 
Water Heat Calculations 
Heat Required by Water (J) 0.85 
Water Heat Capacity (J/kgK) 4.108 
ΔT water (K) 1.11 
Mass of Water (kg) 0.19 
Volume of Water (L) 0.19 
Volume of Water (gal) 0.05 
Volume of Tank (gal) 0.10 
Time in Thawing (min) 2 
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the steam vents to atmosphere so a full boiler system is not needed. This was done because the 
steam generated is so small, it is more cost effective to generate more steam than to install an 
entire boiler system. Heating coils were used to generate steam because electricity is a cheaper 
utility than fuel gas.25  
 
Cryogenic Storage/Preparation: 
Both the purchased adult iPSCs and the final NSCs must be kept in cryogenic storage 
until use or shipping, respectively.3 Liquid nitrogen is used to keep the stem cells at the desired 
temperature. The stem cells are stored in a 24K Cryostorage System by MidSci.1 This system 
was chosen due to the low cost compared to other products and its large storage capacity of 
24050 2 mL vials. The storage units use SS as a material of construction and have a liquid 
nitrogen capacity of 365 L. Three storage units were selected to account for large hold up of the 
inlet adult iPSCs; the NSCs and iPSCs are stored in separate storage units to avoid cross 
contamination of stem cells. Due to a significant evaporation rate, excess liquid nitrogen for the 
storage units is kept in an exterior tank. The exterior tank was sized based on the need to refill 
the Cryostorage tanks every 52 days.1 This is a common heuristic used for liquid nitrogen 
storage. This calculation led to a necessary size of 1500 L; however, nitrogen storage tanks have 
nominal sizing so a tank with a volume of 1893 L (3000 gal) was used. The exterior tank was 
assumed to be pressurized to 200 psig, based on literature values.11 Due to the incredibly low 
temperature of the nitrogen, insulated stainless steel was used for the MOC. A refrigeration 
vessel was also incorporated to prepare the NSCs for cryogenic storage. The CryoMed 
Controlled Rate Freezer was used because of its FDA certification and stainless steel 
construction. The freezer has a max liquid hold up of 34 L which is the smallest unit than can 
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hold the entirety of the product in one batch. The freezer also can full chill to cryogenic 
conditions at -150o C and has a small electrical requirement of 120 V and 60Hz.  
 
Viral Inactivation Tank: 
A major issue with pharmaceutical manufacturing is the potential for the presence of 
viruses in the medical treatment. To reduce this potential, a viral inactivation tank was placed 
before the cell separation. The tank uses a sparger to distribute gaseous formaldehyde throughout 
the NSCs to kill off any viruses. The tank maintains a formaldehyde concentration 0.2 g/L for 2 
hours to ensure complete virus inactivation. A sparger was necessary to ensure even distribution 
of formaldehyde throughout the media due to the natural mixing inherent to a sparger. Also, a 
sparger avoids having to spend extra money on an agitator for the tank. In order to reduce batch 
time, the inactivation tank was sized identically as differentiator to a volume of 108 L so the 
entirety of the 52 L batch could fit in the tank and only half way fill the tank. The tank was 
assumed to be at atmospheric pressure and is constructed from stainless steel to prevent 
corrosion and contamination.  
 
Pumps: 
Eight pumps were added throughout the process to ensure consistent volumetric flow 
rates. A major issue with the use of pumps is the shear stress caused by the impeller damaging 
the stem cells. To avoid cell damage, peristaltic pumps were used in place of traditional 
centrifugal pumps. The low shear of peristaltic pumps make them ideal for pumping cell media 
through the process. Since peristaltic pumps do not significantly increase the pressure of the 
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working fluid, sizing was based entirely off the volumetric flow rate of 1.75 lpm.  The Vector 
2004 model peristaltic pump is used for all 8 pumps. 
 
Cell Separator: 
While the cell differentiator provides nearly 100% conversion from iPSCs to NSCs, 
separation of undifferentiated cells from NSCs is still necessary. A CliniMACS Prodigy cell 
separator is used to purify the cell product stream before being chilled. The cell separator uses 
magnetic-activated cell sorting to differentiate the neural stem cells. This is done by using 
magnetic antigens with metal attached to cause to allow a magnetic field to separate the NSCs 
from other cells. The device has a MOC of HDPE (high density polyethylene) and is design in 
accordance with the Miltenyl Biotec company standards.  
 
Expansion Chambers: 
Due to the limited feed stock, multiple expansion chambers are needed to produce the 
requisite number of cells before differentiation. The expansion is done in 5 parts with 4 
expansions done on a bench top scale and the final expansion done in a large tank. Each 
expansion chamber was sized to start expansion with an initial cellular density of 100,000 
cells/mL and end with a cellular density of 1.2 million cells/mL.8 These densities were chosen 
based to coincide with the original starting density and the maximum cellular density possible 
while still ensuring cellular vitality.8 Residence time in each chamber was determined by using a 
logarithmic function to model the time needed for the cell density to change from the starting 
density to the final density. The residence time for each expansion chamber can be seen in the 
Appendix. The original minimum number of chambers was only 4; however a 5th expansion 
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chamber was added to ensure none of first four chambers would be undersized and to account for 
future international market expansion. The first four expansion chambers are placed in laminar 
flow cabinet, along with a single bench-scale centrifuge for separating the concentrated stem 
cells from used media. The final expansion chamber feeds to an automated centrifuge which 
concentrates and separates the expanded stem cells from the media.  
 
Bioreactor: 
The GE XDR-200 Bioreactor Complete by GE was chosen as the cell differentiator for 
the process. This reactor type was chosen because of the known cost of the vessel and that it 
satisfactorily meets requirements to differentiate iPSCs into NSCs. A reactor size of 200L was 
chosen because it was the smallest nominal reactor volume that was still at least double the size 
of the process fluid.  
It was deemed appropriate that the reactor be at least double the 52L volume of the cells 
and media to ensure over-pressure events and backflow through the vents or reactors could be 
avoided. The differentiator is a batch reactor which uses an agitator to stir the suspended cells in 
the differentiation media and operates at 37ºC and atmospheric pressure respectively. The batch 
reaction has a residence time of seven days based on media specifications which illustrate the 
time necessary for iPSCs to differentiate into NSCs.  
 
Centrifuges: 
Three centrifuges were placed in the process to concentrate and separate cells from 
media. The first centrifuge is a bench top-scale size with a volume of 0.03m3 and has individual 
vials in which the media and cells can be placed during centrifugation. The second and third 
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centrifuges follow the final expansion chamber and the bioreactor, respectively. Centrifuges 
were sized to not operate over 3000 RPM and 300 RCF to prevent damage to cells.  The 
requirement of low shear is satisfied at these conditions.  All centrifuges were sized by assuming 
an L/D of 4 and using solver by changing settling velocity to determine an overall volume and a 
distance away from the center of the expansion chamber. The final volumes of the Centrifuges 2 
and 3 are 0.05 m3 and 0.08m3, respectively. 
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Equipment Specification Sheets: 
 
 










Cells to 1.2*106 
Cells 37 °C 1.01 Bar 962.11mm Plastic
TF-100 Expansion Chamber
T Flask    Second  
Expansion Takes 
1.2*106Cells to 
1.44*107 Cells 37 °C 1.01 Bar 19mL Plastic
SF-100 Expansion Chamber
Spinner Flask 
Third  Expansion 
Takes 1.44*107 
Cells to 1.73*108 




Takes 1.73*108  
Cells to 2.07*109 





Cells to 3.14*109 
Cells 37 °C 1.01 Bar 40L SS
BR-300 Differentiator
Converts iPSCs to 




damaging cells 37°C 1.01 Bar 200L SS
R-300 Media Prep Tank
Prepares Cells for 
Cryostorage -150°C 1.01 Bar 20L SS
WWB Warm Water Bath
Thaws iPSCs out 













Table 10-Pump Equipment Specification Sheet 
















cells and media 
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BR-300
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R-300
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BR-300








Table 11-Pump Equipment Specification Sheet 
 
Table 12-Pump Equipment Specification Sheet














Feeds cells and 
media to  C-201
0.13 1159 SS
Equipment Specification Sheets-Centrifuges
Equipment Tag Category Description Temperature Pressure MOC
LFC Sanitation
Provides clean 





















Cools NSCs for 
Cryostorage
-150°C 2.02bara SS
Equipment Specification Sheets-Support Systems
 
 
Page 34 of 136 
 
 
Equipment Cost Summary:  
 Generally, biomedical facilities have smaller capacities than standard chemical plants, but 
the price per area is significantly more expensive due to the need for highly specialized 
equipment and tight physical constraints on the product.7  In particular, the neural stem cell 
production facility must be consistent with the current good manufacturing practices as outlined 
by the FDA.9,18  Maintenance of the facility is paramount not only to manufacture a quality 
product, but to ensure the health and safety of the employees on site.  A distribution of the fixed 
capital investments can be seen in Figure 6. 
 
Figure 6-Distribution of Fixed Capital Investment 
  
Figure 6 does not include the capital investment for the boiler unit or the cost of facility 
construction due to the magnitude of each item.  Proper cleanliness/manufacturing of the facility 
is vital to maintain the integrity of product because a significant portion of the process is open to 
atmosphere.  For example, high efficiency particulate air resistance (HEPA) systems are used 
throughout the facility in order to keep the air quality consistent with current good manufacturing 
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practices.  Multiple HEPA standard air filters are installed in the air lines to ensure that the air 
does not contaminate the process.  However, compared to the construction cost of the facility, the 
cost of the ventilation system is relatively insignificant.  The cost of the air purifiers is estimated 
at $14,400 for the entire system.   
 Similarly, the most important piece of equipment in the process is the bioreactor because 
it is the source of revenue generation.  The reactor takes induced pluripotent stem cells and 
differentiates them into neural stem cells using a neural induction medium.  Tight parameters 
such as pH, oxygen, and temperature must be stable in order to ensure maximum viability of the 
stem cells.23 These process variables are maintained by installing control systems.  Furthermore, 
the reactor needs to be constructed from stainless steel to provide enhanced corrosion and fouling 
protection.  Altogether, the reactor estimate is $259,600.  
Although the product of the bioreactor is what ultimately makes the process economical, 
the expansion chambers allow the process to generate the volume of stem cells needed to meet 
market demands.  The process starts at 100,000 cells and expands to over three billion cells 
based on the doubling time of the cells.16 This process is time consuming and needs to be done as 
efficiently as possible.  However, a single expansion chamber cannot be used because the 
process cannot be controlled appropriately. Therefore, five expansion chambers are used to 
slowly grow the process from a volume of 1 mL to 25 L.  The first four of these chambers are 
disposable and range in size from a 35mm cell culture plate to a 3 L plastic vessel.  Since the 
chambers are disposable, it is more economical to replace them after each batch rather than 
adding downtime to steam treat the chambers.  Each year it is estimated that the disposable 
expansion chambers costs $7600.  However it is not economical to replace the 40L expansion 
chamber after every batch. Therefore, a permanent vessel is installed to minimize the capital 
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investment of the project.  However, the vessel needs to be steam treated after each batch.  
Stainless steel is used in place of plastic to provide a more structurally sound and durable vessel.  
The last expansion chamber is expected to cost $153,000.  
 Subsequently, centrifuges provide separation of materials with different densities.  For 
pharmaceutical processes, centrifuges are invaluable because they allow for fine separation 
between the product and other materials.  With regard to neural stem cells production, the unit 
consists of three centrifuges that vary in size to handle different volumes of fluid.  The first 
centrifuge is a closed system, where the process is put into a vial compatible with the centrifuge.  
The last two are open systems where the stem cells stick to the outside of the unit while the 
waste passes through. The cells are then washed to force them into the next step of the process.  
The cost of the three centrifuges combined is estimated at $38,700. 
 The kill tank can be modeled as a vessel even though it reacts with protein coating on 
viruses to inactivate them. Formaldehyde is bubbled through the vessel using a sparger to ensure 
the stem cells do not have viruses in solution.  The viral inactivation chamber is made of 
stainless steel for quality and durability and is estimated at $40,100.   
After viral inactivation, the product goes to a cell separation unit that removes 
undifferentiated stem cells and excess media from the neural stem cells.  This unit is estimated at 
$76,700 and gives a high purity product.   
 Lastly, the cells are sent to a vessel that adds dimethylsulfoxide to ensure proper 
cryopreservation of the neural stems cells.15 These cells are then refrigerated in a different unit to 
bring them to cryogenic storage conditions.  The combined cost of both of these units is 
estimated to be $42,000.   
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 Storage conditions are key to maintaining the cells in cryogenic state and liquid nitrogen 
is used to keep the cells at these conditions. Storage tanks are utilized to store the cells in the 
vapor phase of liquid nitrogen.15 The initial storage tank holds 100,000 induced pluripotent stem 
cells. The final storage tank holds 365L of liquid nitrogen to preserve the final volume of cells 
before shipping.  Also, a large liquid nitrogen storage tank needs to be present on site to provide 
fresh liquid nitrogen to account for heat losses in the Dewar.  Altogether, there are three liquid 
nitrogen storage tanks that have been estimated to cost $101,000.   
 Steam needs to be generated to sterilize all non-disposable equipment and hot water is 
needed to maintain a constant temperature in the bioreactor.  To do this, a boiler must be 
installed to produce steam.  The estimated cost of the boiler has been estimated to be 
$16,800,000.  Lastly, there needs to be work done on the process in order for the fluid to be 
transferred for automated parts of the facility.  Eight pumps are placed in locations where 
material needs to be transferred from one location to another where manual transfer is either 
impractical or inefficient.  Each pump provides the same volumetric flow rate and the same 
discharge pressure; therefore, the cost of each pump is the same.  In total, the pumps are 
estimated to cost $122,000.   
 The total equipment cost is approximately $18 million.  This accounts for units in the 
process, and all units needed to maintain the integrity of the process as well as utilities.  
 
Fixed Capital Investment Summary: 
 The most expensive part to the entire facility is the building in which the facility is 
enclosed.  It is also the largest portion of the capital investment.  For this particular project, the 
building must be incompliance with Class 1000 GMP Production Facility protocol to meet 
 
 
Page 38 of 136 
 
 
standards.8 The price of the lab can be estimated based on an average laboratory size with above 
average cost per gross square foot (gsf).  In 2014, the average cost per gross square foot was 
$725-834 and facility size ranged from 100,000-200,000gsf.  By choosing a 150,000gsf facility 
that costs $800/gsf, the facility can be estimated to cost around $100 million.8  The relatively 
high estimation stems from two key factors: the large space required for the pharmaceutical 
process and the high standard for cleanliness.  In comparison, the cleanliness of the facility is 
that of a hospital operating room.  This increases the cost of the facility considerably.   
Moreover, the equipment listed above describes the bare modulus cost. However, there 
are additional costs to consider that are independent of the cost of production.  Turton et. al. 
generalizes these costs into a “contingencies and fees” category.  Included in this category are 
costs for shipping, installation, and labor that arise after the piece of equipment is built.25 The 
result of these additional costs is the total installed cost.  An 18% rate of contingencies and fees 
is assumed for this project in accordance with heuristics in Turton et al.  The total installed cost 
is a function of the bare modulus cost as seen in Equation 3. 
𝐶𝑇𝑀 = 1.18𝐶𝐵𝑀          (3) 
Where: 
CTM = Total Installed Cost 
CBM = Bare Modulus Cost 
Stainless steel was chosen for this process because the higher quality metal provides the 
corrosion resistance needed to keep the process clean while still being relatively inexpensive.  
Moreover, carbon steel introduces rust into the process over time; therefore, a higher quality 
metal is installed in piping to keep the process clean. Other exotic metals would perform better, 
but stainless steel is compatible with the system and the most economical option.  Since piping is 
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in contact with the process, stainless steel is used to prevent contamination.  The cost is not 
estimated in this report because not enough information is known regarding the physical layout 
of the facility, but an upgrade in piping metallurgy needs to be taken into economic consideration 
when the detailed design phase begins.  A summary of the fixed capital investment can be seen 
in Table 13.  The costs included in the table are the total installed cost of each piece of 
equipment. 
 
Table 13-Summary of Fixed Capital Cost 
 When batch size is small the process needs to be controlled manually, but when the batch 
is large enough, it can be controlled more precisely through automation, introducing an extra cost 
in the fixed capital. Similarly, automated parts of the process are controlled via a distributed 
control system.  Specifically, the bioreactor and the final expansion chamber have control 
systems designed to keep the process at optimal conditions.  These conditions are very sensitive 
Bioreactor 259,600$               
Permanent Expansion Chamber 153,400$               
Small Centrifuge 12,900$                  
Medium Centrifuge 15,300$                  
Big Centrifuge 17,500$                  
Kill Tank 40,100$                  
Cryopreparation Tank 17,500$                  
Liquid Nitrogen Storage Tank 84,300$                  
Boiler Unit 19,722,000$         
Refrigeration Unit 24,780$                  
Cryo Storage Unit 16,190$                  
Cell Counter 153,400$               
Laminar Flow Cabinet 14,285$                  
HEPA Filters 19,580$                  
Warm Water Tank 3,500$                    
Peristaltic Pumps 122,000$               
Cell Sorter 76,700$                  
Facility Construction 101,422,000$       
Fixed Capital Cost Summary
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and directly affect the viability of the stem cells.  Also, error is increased when operators have 
more interaction with the process.  However, the process cannot be fully automated due to the 
small volume of the early processes.  Automating the process would cause some material to not 
be transferred, causing a significant decrease in the yield of a batch.  On the same hand, extreme 
delicacy is required for the early stages of the batch process, which cannot be accomplished with 
automation.  This becomes favorable when the batch is larger because human control becomes 
more difficult as the capacity increases.   
 To estimate the cost of the control systems for the facility, a standard estimation was used 
and added onto the installed cost of the equipment.  This includes the control valve, logic 
controller, measurement device, and the electrical wiring.  Automated controls are critical on the 
bioreactor, where temperature, oxygen concentration, and pH need to be tightly controlled.  
Ultimately, significant extra expenses apart from the cost of equipment need to be considered 
when determining the economic viability of a project.     
 
Safety, Health, and Environmental Considerations: 
A unique set of parameters are required for facilities with biological components are 
required to satisfy OSHA and FDA requirements.  Keeping all employees safe and protecting the 
environment is the most important priority for the facility.  Failure to do either of these results is 
unacceptable in operation. Material that is not sent to the packaging and formulation group needs 
to be treated properly in order to comply with environmental regulations.  From an 
environmental standpoint, biological waste needs to be handled properly to prevent widespread 
contamination, but non-biological waste is still treated with the normal precautions.  Biological 
material needs to be inactivated before other disposal methods can be implemented.  However, 
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there are some materials that are not compatible with the sewer system regardless of the presence 
of biological organisms.9 Specifically, DMSO is not compatible with the sewer system and needs 
to be disposed in an organic waste container.  Ultimately, an operating procedure detailing the 
disposal methods for each material in the process is created to prevent incidents in the facility.   
 Health of employees is maintained through proper operating and safety procedures.  
Employees handling hazardous chemicals will wear the proper personal protective equipment as 
outlined by the materials safety and data sheet.  Proper handling of biological waste is critical 
because it presents a unique hazard.  All biological waste is inactivated via formaldehyde or 
steam treatment. A table outlining the material properties present in the facility can be seen 
below.  Most materials do not present high risk hazard and are handled by the process design. A 
















Table 14-Material Properties Summary 
Since very low temperatures are used for cell preservation, proper protective equipment 
is used to prevent skin damage due to contact from liquid nitrogen. Likewise, DMSO is an 
incredibly miscible solvent and diffuses through skin upon contact. Other hazards originate from 
low pressure steam and other cleaning procedures. Low pressure steam generated from the boiler 
unit causes burns when exposed to open skin. Therefore, procedures are placed around the 
stream outlet.  All materials safety and data sheets are onsite and readily available in an effort to 
keep all operators safe and knowledgeable. The material safety and data sheets are also included 
in the Appendix.   
 Moreover, the process is designed to keep all material inside of the pipes through units 
that are closed systems.  The controls system is designed to keep the process variables at the 
desired set points, prevent contamination, and maintain the integrity of the facility.  However, 
some parts of the process have to be performed manually.  Operators and lab technicians will be 
Material Molecular Weight (g/mol) Normal Boiling Point (
oC) Flammability Limit (%) Flash Point (
oC)
Induced Pluripotent Stems Cells - - - -
Neural Stem Cells - - - -
Expansion Media - - - -
Reactor Media - - - -
Trypsin 23.3 kDa Denatures at 50oC N/A N/A
Dimethylsulfoxide 78.13 189 2.6-3.5 50
Formaldehyde 30.03 -19 7.0-71.0 60
Nitrogen 28.02 -195.8 None N/A
Water for Injection 18.02 0 None None
EDTA 292.24 614.2 None 93.3
Material Autoignition Temperature (
oC) Liquid Density (kg/m3) Reactivity with Water Toxicity Limits (ppm)
Induced Pluripotent Stems Cells - 1125 - -
Neural Stem Cells - 1125 - -
Expansion Media - 1100 - -
Reactor Media - 1100 - -
Trypsin N/A N/A Soluble None
Dimethylsulfoxide N/A 1101 Hygroscopic 7920
Formaldehyde 430 1080 Soluble 42
Nitrogen None 807 None N/A
Water for Injection None 1000 N/A N/A
EDTA N/A 860 Soluble N/A
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trained on how to perform the critical, manual steps in the process as well as emergency 
shutdown procedures.  The NOAA provides an interaction matrix where a hazards associated 
with chemicals can be simulated.  Table 15 shows the results of the interaction matrix. 
 
Table 15-Interaction Matrix Depicting Material Compatibility 
 
The results indicate that the only incompatible materials are formaldehyde and EDTA; 
therefore, these materials need to be separate to prevent incompatible mixing of chemicals.  
EDTA is used in conjunction with trypsin to remove the cells from the bioreactor to send it to the 
inactivation tank, which has formaldehyde.  However, the reaction does not occur at the 
concentrations present in the tank.  If the concentrations are ever increased, EDTA is removed 
from the system in order to keep the process safe.   
A key part of maintaining the scheduled production rate is the downtime, where operators 
need to sterilize and clean equipment efficiently to minimize the shutdown time.  To ensure 
minimal downtime, all personnel are trained on FDA cGMP practices and facility procedures 
prior to starting work.4 In addition to the procedures in place to prevent a workplace injury, 
inherent safety considerations have been included in the design to minimize the potential for an 
accident.  A summary of these inherent safety procedures can be seen in Table 16.  The hazards 
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seen below address designs within the system and outline the action needed to safely deal with 
each hazard in the facility.   
 
Table 16-Summary of Inherent Safety Designs 
   Particularly, pinch hazards arise when maintenance is performed on centrifuges and 
peristaltic pumps. Therefore, sufficient training in maintenance and repairs is needed to simplify 
the process.  Furthermore, the steam used for cleaning is an open system and extra protective 
layers are installed to keep operators safe.  Hot work gloves are worn at all times to prevent 
burns to the skin in addition to standard PPE.  Implementing inherent safety concepts within the 
design of the facility minimizes the risk of recordable injuries. 
All cleaning procedures are in compliance with FDA standards and provide the company 
with a safe working environment as well as sterile biological products.  Any vessel that contains 
biological material is steam cleaned for 3 minutes as per FDA guidelines21. Any material sent to 
the sewage system is subject to the constraints set by the city.  Regardless of regulations, no 
living organisms can be sent to the sewer. Therefore, living waste is treated by inactivation via a 
detergent before it is properly disposed.  Table 17 below summarizes the potential consequences 
associated with failing to prevent hazards present in the process.  The consequences are assessed 
on a “Low-Medium-High” Scale.  
 
Hazard Inherent Safety Concept Action
Extreme storage temperatures Simplification Implement concise operating procedure
Biological material Attentuation Maximize automation of process/dilute material before treatment
Toxic Cryopreservative Minimization Automated Injection Volume
Low Pressure Steam Moderation Calculate volume to sterilize equipment
Toxic Waste Attenuation Dilute waste before disposal
Atmospheric Contamination Substitution Utilize high purity air/water instead of tap water/ambient air
Mechanical Simplification Sufficient training in operation of centrifuges/pumps 
 
 




Table 17-Potential Consequences Summary Table 
The first measure that needs to be taken in order to comply with current good 
manufacturing practices is HEPA quality air within the facility.  Air circulating in the facility is 
required to be medical grade to prevent stem cell contamination and ensure maximum growth.  
Furthermore, water for injection is required for any application where water comes in contact 
with cells to prevent contamination as well.  The water needs to be as pure as possible since it 
will be injected into patients with the stems cells.  FDA standards require an increase in the 
purity of water from that of tap water4.  Moreover, existing safeguards are used in order to 
minimize the risk within the process.  Stainless steel is used in place of carbon steel for all 
permanent process equipment to prevent corrosion or contamination and plastic or glass is used 
for all disposable parts.  Also, operators are required to wear special personal protective 
equipment to prevent contact with the cells.  This prevents contamination of both the operator as 
well as the stem cells. All of these materials are the result of an inherently safe facility9.  
In conclusion, there is no potential for project termination based solely on safety 
concerns.  However, the process needs to be approved in the United States in order for the 
project to begin. Currently, any treatment involving the usage of stem cells is not permitted by 
the FDA. Operator training is critical because of the delicacy of the process and must be 
significant.  As a whole, the facility present no significant safety dangers to the employees or 
surrounding community.  Overall, proper safety and environmental procedures will be followed 
to ensure a safe, efficient work environment. 
Hazard Equipment Damage Environmental Compliance Loss of Life Disruption of Other Business Units Legal/PR Community Impact
Biological Waste in Sewer - Medium - - High High
DMSO Release - Low Low Low Low -
Formadehyde Release - - Low Medium Medium -
Contamination of Process - Medium - High - -
Steam - - Low - Medium -
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Other Important Considerations: 
 In order to meet production needs multiple batches a year are needed. This requires 
finding the proper amount of batches as well as the scheduling of each batch. To do this, each 
step in the batch must be timed and the next step ready as soon as the previous is done. The trick 
in scheduling is finding when to start the next batch. To accomplish this task, Intelligen SuperPro 
Designer is used. The software allows for input of process and time steps in a batch operation. 
The chart tools can then find a schedule that allows for the calculated number of batches to be 
achieved. After building a simulation a Gantt chart was generated using SuperPro. This chart is 
seen below in Figure 6. From Figure 6, it can be seen that there is an overlap of 169 hours that 
was determined by the software. This accounts for the time to set up and clean the vessels from 
the previous batch as well as start the next. There is also a service factor of 0.75 accounted for in 
this batch timing for FDA inspections and equipment maintenance during the year to comply 
with cGMPs. Figure 7 below also shows the time steps for each process in the batch with time 
amounts in hours next to each step. The longest by far is the differentiation but the early 
expansions take a considerate amount of time of the batch as well.  
Another important decision made during evaluation of this project was the choice of 
expansion medium and differentiation medium. The expansion medium was chosen to be 
Essential 8 from Thermo Fisher. This media was selected because of the success in growing 
large numbers of pluripotent stem cells through multiple passages with no karyotype issues 
found. In conjunction this media does not require extra CO2 for the buffering system. The 
differentiation media was chosen to be Gibco PSC Neural Induction Medium. This medium was 
selected for availability and functionality of turning pluripotent cells into neural stem cells. This 
media is widely available for purchase from Thermo Fisher in large amounts that are needed. 
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This media also has the functionality that is needed to induce PSCs to neural stem cells. This 
makes it a top choice for induction. Also there is no CO2 needed for buffering thereby reducing 
the cost of operation. Another reason is that while the cells are being differentiated they are still 
able to expand by a factor of 20 with this media over the course of 7 days. This is also a shorter 
time span than other mediums used for induction.  The properties described above make the two 









Figure 6-Gantt chart for Yearly Production 
 
 





Figure 7-Batch process time sheet
 
 




 Cost of manufacturing can be divided into three categories: direct costs, fixed costs, and 
general expenses.  Direct costs and fixed costs make up operating expenses that change with the 
rate of production and costs that are independent of changes in production rate, respectively. 
While general expenses represent the overhead required to perform everyday business function.   
 Total costs can be estimated as the sum between the three types of cost seen above.  The 
formula for calculating the total costs is given by Turton et. al. is seen in Equation 4.25 
 
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 = 𝐶𝑅𝑀 + 𝐶𝑊𝑇 + 𝐶𝑈𝑇 + 2.215𝐶𝑂𝐿 + 0.19𝐶𝑂𝑀 + 0.146𝐹𝐶𝐼 + 𝑑𝑒𝑝𝑟𝑒𝑐𝑖𝑎𝑡𝑖𝑜𝑛        (4) 
Where: 
CRM = Cost of Raw Materials 
CWT = Cost of Waste Treatment 
CUT = Cost of Utilities 
COL = Cost of Operating Labor 
COM = Cost of Manufacturing 
FCI = Fixed Capital Income 
 By estimating total manufacturing costs, the day to day plant operation costs can be 
estimated.  
 Operating labor provides a significant capital and personal investment.  Highly skilled 
operators are required for this process, which makes their services more expensive.  Simply 
having the skills is not enough; operators must be trained specifically to the process.  The 
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𝑁𝑂𝐿 = (6.29 + 31.7𝑃
2 + 0.23𝑁𝑁𝑃)
0.5       (5) 
Where: 
NOL = Number of Operators per shift 
P = Number of Processing Steps that Involve Handling of Particulate Solids 
NNP = Number of Nonparticulate Processing steps 
 The pieces of equipment can be summed and plugged into Equation () to show a need for 
four operators per shift.  For the stem cell manufacturing facility, there are no steps that involve 
handling of particulate solids.  Moreover, pumps and vessel are not included in account for NNP 
in Equation 5.   
 Operators for this process need to be extensively trained and highly skilled in order to 
operate the process efficiently and precisely.  Therefore, it is assumed that their average salary is 
significantly higher than that of an average operator.  A salary of $110,000 per year is used in 
order to estimate the total cost of operating labor.  Lastly, Equation 5 produces a need for four 
operator on site at all times.  Turton et. al25 uses Equation 6 to estimate the total number of 
operators needed to be hired for the manufacturing facility.   
 
𝑇𝑜𝑡𝑎𝑙 𝐻𝑖𝑟𝑒𝑑 𝑂𝑝𝑒𝑟𝑎𝑡𝑜𝑟𝑠 = 4.5 𝑁𝑂𝐿        (6) 
 
Eighteen operators will be hired to run the facility at all times.  Therefore, the total cost 
of operators per year is estimated to be $2,000,000.  As seen in Figure 8, the cost of operating 
labor is a large percentage of the total manufacturing cost associated with a facility. 
The utilities costing was done with information given in the AIChE National Design 
competition memo.  Utilities for the neural stem cell manufacturing consist of boiler feed water, 
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water for injection, electricity, sewer water, and liquid nitrogen.  Boiler feed water is used to 
provide low pressure steam to sterilize all non-disposable equipment after each batch as well as 
maintain isothermal conditions in the bioreactor and expansion chamber.  Electricity is used to 
power the boiler unit, peristaltic pumps, centrifuges, and agitators in the bioreactors.  
Furthermore, water for injection is added to the stem cells in order to store them at the 
appropriate concentration.  Usage of the sewer is used for disposal of waste that is compatible 
with city sewer systems; other waste must be treated before other disposal method are 
incorporated.  Lastly, liquid nitrogen is used to keep stem cells at cryogenic storage conditions.  
A summary of the utilities can be seen in Table 18 below. 
 
Table 38-Estimated Yearly Utility Costs 
 All yearly costs are in 2016 dollars and account for all utilities needed to perform the 
process.  Utilities that are used outside of the process are not included due to lack of knowledge.  
For example, the electricity used for lighting in the facility is not included because not enough 
information is known presently.  Ultimately, utility costs make up a relatively small amount of 
the total yearly manufacturing costs.   
 Pharmaceutical manufacturing facilities tend to have more raw materials than standard 
chemical plant due to the number of additive for the process. Although the induced pluripotent 
stem cells are relatively cheap, other raw materials are significantly more expensive such as 
media.  Table 19 below summarizes the yearly cost for raw materials. 
Utility Cost Data Total Yearly Cost 
Electricity (per kWhr) 5.00$                      10,678$                  
Sewer (per 1000 gal) 5.00$                      5.22$                       
Water for Injection (per 1000 liters) 1,000$                    7,600$                    
Liquid Nitrogen (per liter) 0.25$                      1,734$                    
Boiler Feed Water (per 1000 kg) 2.45$                      0.20$                       
 
 




Table 19-Summary of Yearly Raw Material Costs 
 The other factor taken into consideration in Equation 4 includes estimations based on the 
cost of manufacture and fixed capital investment.  These play a significant role in the 
manufacturing cost of the process, and have been calculated in previous sections.  The Figure 
below illustrates the proportions of the three types of cost present in the facility. 
 
Figure 8-Distribution of Manufacturing Costs 
 Even though depreciation is included in the formulation of these costs, Figure 8 does not 




Raw Material Yearly Cost
Induced Pluripotent Stem Cells 1,753$                    
Expansion Media 328,028$               
Differentiation Media 4,600,620$            
Trypsin w/ EDTA 1,313$                    
Formaldehyde 33,526$                  
Dimethylsulfoxide 180,804$               
 
 




 The driving force behind this project is the economic benefit to the company undertaking 
the risk of pursuing it. The minimum rate of return given that the project must pass to be 
profitable is 50%. This represents the minimum amount of return that the project could support 
before outside investment would be more profitable to pursue.  
 The following section details the capital estimation of the equipment that could not be 
directly cost from the AICHE GE spreadsheet. The methods used are consistent with Turton et. 
al.25 for costing equipment. A list of equipment not costed from GE are seen below in Table 20 
with the classification for sizing with key sizing parameter.  
 
Table 20-4EquipmentCcosted from Turton et. al. 
For costing these pieces of equipment, Equation 7 below was used from Appendix A.1 in 
Turton25. This equation calculates the equipment free onboard cost or the manufacture cost 
without shipping included in 2001. To move from 2001 to 2016 dollars the CEPCI was used. The 
values for the CEPCI is seen below as well. The CEPCI is used by dividing the current by the 
past and multiplying this ratio by the Cp amount.  
 
Table 215-Costing factors for equipment 
log10(𝐶𝑝) = 𝐾1 + 𝐾2 log10(𝐴) + 𝐾3(log10(𝐴))
2                                (7)                    
Where: 
 Cp = Bare Bones Cost 
Equipment Classification Key Parameter
Boiler Electric Heater kW
Peristaltic Pumps Positive displacement pumps kW
Equipment K1 K2 K3 CEPCI 2001 CEPCI 2016
Centrifuges 4.7681 0.974 0.024 397 560
Electric Heater 6.9617 -1.48 0.3161
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Ki = Cost Factor  
A = Key Sizing Parameter  
The next step to cost these pieces was to account for the MOC and the pressure 
requirements of the equipment. Since pressure was low for both pieces of equipment the pressure 
factor was determined to be 1. The costing equation for total installed cost is seen below for both 
pieces. Equation 8 is used for centrifuge sizing while Equations 9 and 10 is for the steam boiler. 
The boiler has special considerations as the steam superheat temperature is critical to cost of 
manufacture.  The bare module cost takes into account the piping, controls, and instrumentation 
needed for these pieces of equipment as well as the cost of the unit and shipping.  
𝐶𝑏𝑚 = 𝐶𝑝𝐹𝑏𝑚            (8) 
𝐶𝑏𝑚 = 𝐶𝑝𝐹𝑏𝑚𝐹∆𝑇           (9) 
Where:  
Cbm = bare module cost 
Fbm = costing factor for Cbm  
𝐹∆𝑇 = degree of overheat factor from equation 9  
and 
𝐹∆𝑇 = 1 + 0.00184∆𝑇 − 0.00000335(∆𝑇)
2       (10) 
Where: 
 ∆𝑇 = 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑠𝑢𝑝𝑒𝑟 ℎ𝑒𝑎𝑡𝑖𝑛𝑔 𝑖𝑛 𝐶𝑜 
Using these equations the three centrifuges and boiler unit were costed. The boiler was 
the most expensive by far due to the nature of a boiler unit and that it needed to be a certain size 
over required to meet regulations.  
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 The final cost used in discounted cash flow analysis was calculated from Cbm and is 
detailed below in Equation 11. This is the total cost with contingencies and fees. This takes into 
account a buffer of 15% overages on construction or cost of materials and 3% of cost of the 
project in fees. These numbers were chosen as a representative sample of normal project 
planning guidelines discussed in Turton et. al25. This gives a total of 18% for the over estimation 
of the overall cost of each piece of equipment.    
𝐶𝑡𝑚 = 1.18𝐶𝑏𝑚          (11) 
Where: 
 Ctm = total cost with contingency and fees  
Cbm = bare module cost  
 The application of these equations to three centrifuges and the steam boiler is seen below 
in Table 22. The centrifuges are of average to small size for bioprocesses. The first one is a small 
bench top model that uses disposable vials. The second is a larger bench top model that uses 
larger half liter to liter centrifuge vials but is still manual. The third centrifuge process the cells 
produced by the fifth expansion chamber and is made of stainless steel and is not disposable. The 
MOC for the boiler is carbon steel and the thickness is consistent with the pressure. The Cp, Cbm, 











Table 22-Cost of Equipment 
 Incorporating cost calculated with the costs sourced from the GE data gives a total capital 
estimate of $21,260,000; this does not include the building cost. The boiler was the largest 
individual cost at $19,720,000. This can be attributed to the cost of all of the controls and piping 
needed for this system. A summary of equipment costs can be seen in Table 23 below; the items 
highlighted are costed from Turton et al25. All others were costed using GE data as well as 
internet data.  
 
 
Table 236-Total Equipment cost 
Equipment Cp Cbm Ctm Key Paramter
C-100 $12,561.00 $19,721.00 $32,855.00 Diameter= .2 m
C-200 $5,967.00 $9,369.00 $15,608.00 Diameter= .09 m
C-201 $16,088.00 $25,258.00 $42,079.00 Diameter= .26
Boiler $3,949,624.00 $11,848,871.00 $19,722,252.00 Duty (kW)=26349
Bioreactor 259,600$               
Permanent Expansion Chamber 153,400$               
Small Centrifuge 12,900$                  
Medium Centrifuge 15,300$                  
Big Centrifuge 17,500$                  
Kill Tank 40,100$                  
Cryopreparation Tank 17,500$                  
Liquid Nitrogen Storage Tank 84,300$                  
Boiler Unit 19,722,000$         
Refrigeration Unit 24,780$                  
Cryo Storage Unit 16,190$                  
Cell Counter 153,400$               
Laminar Flow Cabinet 14,285$                  
HEPA Filters 19,580$                  
Warm Water Tank 3,500$                    
Peristaltic Pumps 122,000$               
Cell Sorter 76,700$                  
Facility Construction 101,422,000$       
Fixed Capital Cost Summary
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  It is worth noting that no equipment was spared because all equipment is easily ordered 
with quick lead times on shipping.  
 
Revenue: 
 The revenue for this project comes from the sale of the stem cells as therapy. An 
assumption made is that the stem cells can be sold at a bulk price not seen in the current market. 
This means that the current rate of $520.00 is much higher than the therapy cells would sell for. 
Using the current selling price as a reference a final sale price of $250 per million cells to ensure 
a reasonably affordable treatment option for patients. Multiplying this by the number of million 
cells produced a year yields a sales revenue of $230,000,000.  
 In order to determine the minimum sale price of the neural stem cells to achieve a rate of 
return of 50%, a breakeven analysis was performed.  The result of this analysis was a sale price 
of $150 per million neural stem cells.  This confirms that the breakeven analysis is accurate since 
the minimum rate of return given in the memo is 50%.      
DCFROR:  
Combining the revenue and utilities cost with capital investment gives a basis to perform 
a discounted cash flow rate of return analysis (DCFROR). This analysis takes into account the 
tax rate of 40% normally seen as well as depreciation and escalation of equipment and operating 
costs. An escalation rate of 0.86% was determined from the Department of the Treasury, using 
factors published each month. The depreciation rate was done using MACRS for a 5 year 
depreciation life with a half year assumed in year 1.  
 The major factors that affect the DCFROR are building cost, and boiler cost. These two 
costs contribute the most to the initial capital investment that in turn has a large effect on the rate 
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of return and net present value. These costs were minimized then to increase the viability of the 
project. To determine how viable the project is, the DCFROR was compared to the given i* of 
50%. Any DCFROR below this point was deemed unviable for continuation. The project was 
determined to have a NPV of $95,730,000. This gives a DCFROR of 97.8% which is greater 
than i* therefore the project is viable.  
 The cash flow for the project is seen below in Table 25. The company situation was 
assumed to be stand alone as the statement stated that this is being pursued by a small to 
midsized biomedical company. This means that there is loss forward in the event of negative 
taxable income.  
 A return on investment comes when the project starts returning money and no longer 
paying off debts. There are two commonly reported times, which are undiscounted and 
discounted payback periods. The only difference is the discount to account for the time value of 
money. The payback time for the discounted period is found to be 1.27 years while the 
undiscounted is 0.995 years. These both confirm that the project is economically attractive to 
pursue as the return on investment comes before the project is over. A summary of this data is 
shown below in Table 24.  
 
Table 24-7Payback Periods 
Discounted Payback Period 0.995
Undiscounted Payback Period 1.270
Estimated Payback Periods 
 
 




Table 258-Cash Flow Table for Neural Stem Cell Project Life 
Project Title: Neural Stem Cell Therapy 
Corporate Financial Situation Stand Alone
i* 0.5
Other Relevant Info MACRS *Depreciation
1= $1 1/1/2017 1/1/2018 1/1/2019 1/1/2020 1/1/2021 1/1/2022
End of Year 0 1 2 3 4 5
Sales Revenue 0 232,180,000$        234,180,000$         236,190,000$         238,220,000$         240,270,000$         
+Salvage Value 0 0 0 0 0 0
-Royalties 0 0 0 0 0 0
Net Revenue 0 232,180,000 234,180,000 236,190,000 238,220,000 240,270,000
 - Expansion Media Cost 0 (331,000)$               (334,000)$                (337,000)$                (339,000)$                (342,000)$                
 - Reactor Media Cost 0 (4,633,000)$           (4,673,000)$            (4,713,000)$            (4,753,000)$            (4,794,000)$            
 - DMSO 0 (182,000)$               (184,000)$                (186,000)$                (187,000)$                (189,000)$                
- Formaldehyde 0 (33,800)$                 (34,100)$                  (34,400)$                  (34,700)$                  (35,000)$                  
 - Induced Pluripotent Stem Cell 0 (1,800)$                   (1,800)$                     (1,800)$                     (1,800)$                     (1,800)$                     
 - Liquid Nitrogen 0 (6,700)$                   (6,800)$                     (8,100)$                     (6,900)$                     (6,900)$                     
 - 0.05% Trypsin w/ EDTA 0 (21,720)$                 (21,900)$                  (22,140)$                  (22,280)$                  (22,470)$                  
 - Disposable Expansion Chambers 0 (9,157)$                   (9,239)$                     (9,322)$                     (9,393)$                     (9,475)$                     
-Cell Sorting Kits 0 (616,292)$               (621,592)$                (626,938)$                (632,329)$                (637,767)$                
 - Boiler Feed Water 0 (10,800)$                 (10,900)$                  (11,000)$                  (11,100)$                  (11,100)$                  
 - Operating Labor 0 (2,420,640)$           (2,441,458)$            (2,462,454)$            (2,483,631)$            (2,504,990)$            
 - Manufacturing Costs 0 (22,690,000)$         (22,890,000)$          (23,080,000)$          (23,280,000)$          (23,480,000)$          
 - Utilities 0 (19,800)$                 (19,900)$                  (20,100)$                  (20,300)$                  (20,500)$                  
Building Utility Costs 0 (229,961)$               (231,938)$                (233,933)$                (235,945)$                (237,974)$                
 - Depreciation 0 (6,849,313)$           (9,401,047)$            (6,679,197)$            (5,046,087)$            (5,046,087)$            
 - Amortization 0 0 0 0 0 0
 - Depletion 0 0 0 0 0 0
 - Loss Forward 0 0 0 0 0 0
 - Writeoff 0 0 0 0 0 (89,665,477)$          
Taxable Income -$                                                             194,120,000$        193,300,000$         197,760,000$         201,160,000$         113,270,000$         
 - Tax at 40% 77,648,000$          77,320,000$            79,104,000$            80,464,000$            45,308,000$            
Net Income -$                                                             116,472,000$        115,980,000$         118,656,000$         120,696,000$         67,962,000$            
 + Depreciation 6,849,313$             9,401,047$              6,679,197$              5,046,087$              5,046,087$              
 + Writeoff 0 0 0 0 89,665,477$            
-Fixed Capital (122,687,208)$                                          0 0 0 0 0
Cash Flow (122,687,208) 123,321,313 125,381,047 125,335,197 125,742,087 162,673,565
Discount Factor (P/Fi*,n) 1.000 0.667 0.444 0.296 0.198 0.132
Discounted Cash Flow (122,687,208) 82,214,208 55,724,910 37,136,355 24,837,943 21,422,033








 To determine the stability of the project a sensitivity analysis on capital investment, 
operation cost, and selling price. These parameters have the most variability and have a large 
impact on DCFROR. The initial capital investment was varied ±40%. This variance was chosen 
as many of the pieces of equipment are highly variable in cost depending on where it is sourced. 
The operational cost was varied at ±15%. This was chosen as many of the materials are sourced 
from limited vendors with limited stocks. Finally the revenue was varied ±25%. This was chosen 
to be representative of the market as more stem cell therapies are approved so competition will 
increase. 
 To graphically represent this analysis tornado charts are used. They show the variation in 
both the NPV and DCFROR of each situation. Overall this tool is useful to gage the variability in 
the profitability of the project in a dynamic world. Figures 9 and 10 show the NPV and 
DCFROR Tornado Charts, respectively.  
 
 
Figure 9-NPV Tornado Chart 
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The revenue variance has the largest effect on the overall NPV of the project. This is 
normal as revenue is the source of positive cash flow in the project. The capital expense has an 
odd shape around the center, because as at higher estimations the building cost dominates the 
overall expense.  
 
 
Figure 10-DCFROR Tornado Chart 
  The DCFROR tornado shows a much larger dependence on capital expense as 
DCFROR is sensitive to large changes in costs or revenues occurring early in the project. 
Overall, the minimization and negotiation of operating costs and fixed capital investment is key 
to keeping the project profitable moving forward into the future.  
 
Conclusions: 
 Based on the information given in the report it can be concluded that the neural stem cell 
manufacturing facility is economically attractive.  Currently, utilization of stem cells as a type of 
therapy is not allowed in the United States; the only legal application is biomedical research27.  
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Legalization of stem cells therapy will inevitably introduce competition into the domestic 
market.  Proper training is critical to the success of the facility, especially for operator training. 
Although this presents a challenge, the project is economically attractive.  Sensitivity analyses 
and uncertainty calculations produce a rate of return greater than the minimum rate of return.  
Moreover, due to the nature of the process, downtime plays a significant factor in the production 
of the facility. In order to satisfy market demand, optimization of downtime is critical.   
 As with any project, increasing capacity creates an opportunity to capitalize financially.  
The memo states that the facility is looking to expand into European and Asian markets in the 
future, but meeting the demands of the United States is a primary objective.  As designed, the 
facility can meet the demands of the United States over the project evaluation lifetime.  It has 
also been concluded that international expansion in the next 10-15 years is going to produce a 
significant financial opportunity.  However, the facility is designed to handle the additional 
needs of foreign markets. An example of this is the over sizing of the bioreactor.  The unit has 
the ability to handle double the current capacity, while additional expansion can be performed 
without disturbing the original process. 
 
Recommendations: 
 Based on the previous information detailed in the report, it is in the best interests of the 
company to pursue the project.  Small scale testing needs to be done to validate the safety and 
applicability of the project to the Food and Drug Administration.  Also, the company needs to 
wait for legal rulings before significant capital is invested in the project.  Once the patents are 
obtained for the process, the company needs to act quickly to maximize the 20 year life on the 
patent.  Based on the success of the company, an increase in competition is expected once the 
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therapy is approved.  Lastly, significant upfront cost needs to be avoided prior to approval of the 
project by the court. Based on the company’s size, it cannot afford to invest on a project with a 
significant up front cost.  Overall, proceeding with the project is highly recommended; however, 
detailed design of the facility needs to occur after the therapy is legalized. 
 Additionally, the manufacturing facility will most likely need to be scaled up to keep up 
with market demand.  This will call for an increase in capacity, whether that comes from 
modification of the current process or construction of a new facility.  Location of the facility also 
plays a significant factor in the viability of the project.  Regardless of the legal status on the 
project, location provides the company with an economic edge.  Research into the most 
profitable location is highly recommended in order to maximize the viability of cells during 
shipping.  Moreover, legal issues will decrease when the project is expanded into foreign 
markets.  Stem cell therapy is legal is countries across the world and expansion into these 
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Costing and Purchasing Sources: 
 
 "35mm Tissue Culture Dish." 35mm Tissue Culture Dish. N.p., n.d. Web. 06 Mar. 
2016.https://www.abcscientific.com/Tissue%20_culture_dish_35mm 
"50ml Cell Culture Flask T-25 - Plug Cap." 50ml Cell Culture Flask T-25 - Plug Cap. N.p., n.d. 
Web. 06 Mar. 2016https://www.abcscientific.com/cellculture_flask_t25-
plugcap?keyword=flask&category_id=0&model=1 
"Corning® Disposable Spinner Flasks." Disposable Spinner Flask, Polystyrene, Non-treated, 3 
L, W/ Two Sidearms, Sterile, 4/cs. N.p., n.d. Web. 06 Mar. 
2016.http://www.sigmaaldrich.com/catalog/product/sigma/cls3563?lang=en&region=US 
"Corning® ProCulture® Glass Spinner Flask Complete, Baffled, Angled Sidearms." 500 ML 
Glass Spinner Flask, W/ 100 Mm Flat Center Cap, 2 45 Mm Vertical Sidearms, Reusable, 
Non-sterile, 1/cs. N.p., n.d. Web. 06 Mar. 
2016.http://www.sigmaaldrich.com/catalog/product/sigma/cls4500500?lang=en&region=
US 
"Electrocorp I-6500 AH HVAC UNIT." Electrocorp I-6500 AH HVAC UNIT. N.p., n.d. Web. 
06 Mar. 2016. 
Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008."Centers for Disease 
Control and Prevention. Centers for Disease Control and Prevention, 29 Dec. 2009. Web. 
06 Mar. 2016 
GulfGases, Cryogenic Storage." GulfGases, Cryogenic Storage. N.p., n.d. Web. 17 Feb. 2016. 
"Laboratory Fume Hood, Assembled, 70 In." LABCONCO Laboratory Fume 
Hood,Assembled,70 In. N.p., n.d. Web. 06 Mar. 2016. 
"Perforated Pipe Distributor Sizing Calculations." Cheresources.com Community. N.p., n.d. 




























Figure 11-Super Pro Simulation Setup 
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Material Balances/Energy Balances: 
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Figure 12-Basic Control Scheme of Stem Cell Manufacturing Facility 
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Cp $12,561 Cp $5,967 Cp $16,088
K1 4.7681 K1 4.7681 K1 4.7681
K2 0.974 K2 0.974 K2 0.974
K3 0.024 K3 0.024 K3 0.024
A 0.2 A 0.09 A 0.26
Fp 1 Fp 1 Fp 1
Fbm 1.57 Fbm 1.57 Fbm 1.57
Cbm $19,721 Cbm $9,369 Cbm $25,258
Ctm $32,855 Ctm $15,608 Ctm $42,079
Inactivation Tank
Cp $2,081 Cp $2,251 Cp $2,985
K1 3.5565 K1 3.7957 K1 3.4974
K2 0.3776 K2 0.4593 K2 0.4485
K3 0.0905 K3 0.016 K3 0.1074
A 0.0004 A 0.1 A 0.89
Fp 1 Fp 1 Fp 2.2
Fm 1 Fm 3.1 Fm 3.6
Cbm $2,081 Cbm $17,766 Cbm $49,747











Liquid Nitrogen Storage Tank
Final Expansion Centrifuge Small Scale Centrifuge Pre-differentiation Centrifuge
Warm Water Tank
Sized Equipment Costing Summary
 
 















Permanent Expansion Chamber $153,400 1
Disposable Expansion Chambers $9,074 4
Cryopreparation Tank $17,500 1
Refrigeration Unit $24,780 1
Cryo Storage Unit $16,190 1
Liquid Nitrogen Dewer $325 2
Cell Counter $153,400 1
Laminar Flow Cabinet $14,285 2
HEPA Filters $19,580 2
Cell Sorter $76,700 1
Purchased Equipment Costing Summary
 
 



















Equipment Utility Consumed Price per Year
Cryogenic Storage Liquid Nitrogen $6,642
Refrigeration System Electricity $26
Boiler Unit Boiler Feed Water $4
Boiler Unit Electricity $1,317
HEPA Filter Electricity $1,034
Laminar Flow Cabinet Electricity $5,742
Agitator Electricity $64
Utilities Summary
Induced Pluripotent Stem Cells $1,820.20
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Equipment Utility Consumed Price per Year
Cryogenic Storage Liquid Nitrogen $6,642
Refrigeration System Electricity $26
Boiler Unit Boiler Feed Water $4
Boiler Unit Electricity $1,317
HEPA Filter Electricity $1,034
Laminar Flow Cabinet Electricity $5,742
Agitator Electricity $64
Utilities Summary
Equipment Utility Consumed Amount Consumed
Cryogenic Storage Liquid Nitrogen 2562 L
Refrigeration System Electricity 529 kW hr
Boiler Unit Boiler Feed Water 34455 kg
Boiler Unit Electricity 26340 kW hr
HEPA Filter Electricity 10335 kW hr
Laminar Flow Cabinet Electricity 57421 kW hr
Agitator Electricity 1277 kW hr
Utilities System Capital Investment
Boiler Feed Water $/kg 0.00245
Electricity $/kW-hr $0.05





 Boiler Operational Costing*
 
 
Page 78 of 136 
 
 










Initial Number of Cells 100000
Initial Batch Size (mL) 1.00
Initial Concentration(Cells/mL) 100000
Growth Factor 31163
Maximum Cell Concentration (Cells/mL) 1.2 x 10
6
Expansion Batch Size (Cells) 3.14 x 10
9
Total Expansion Residence Time (hrs) 358.25
Individual Expansion Residence Time (hrs) 84
Neural Stem Cells (Cells/Batch) 6.27 x 10
10
Batches per Year 18.3
Total Neural Stem Cells (Cells/Year) 1.151 x 10
12
Basic Process Information
Dose Size (mL) 0.3
Dosage Concentration (Cells/mL) 3.0 x 10
6
Doses per Patient 16
People Treated per Year 62000
Total Cell Demand (Cells/Year) 1.151 x 10
12
Market Demand
Manual Error % 3.0
Service Factor 0.75
Total Working Days Available 273.75
Stem Cell Viability % 80
Batch Processing Information
Expansion Cells Volume (mL) Residence Time (hrs) Total ResidenceTime (hrs)
1 1.20 x 10
6
1 86.0 86.0
2 1.44 x 10
7
12 84.0 174.0
3 1.73 x 10
8
144 84.0 260.0
4 2.07 x 10
9
1728 84.0 346.0
5 3.14 x 10
9
20736 14.5 360.5
Expansion Phase Summary Table
 
 












Phase 1 Volume (mL) Temperature (
oC) Pressure (bar)
Air (Oxygen) N/A 20 1
Media 1 37 1
Trypsin 0.5 20 1
Phase 2 Volume (mL) Temperature (
oC) Pressure (bar)
Air (Oxygen) N/A 20 1
Media 12 37 1
Trypsin 6 20 1
Phase 3 Volume (mL) Temperature (
oC) Pressure (bar)
Air (Oxygen) 0.14 mL/min 20 1
Media 144 37 1
Trypsin 72 20 1
Phase 4 Volume (mL) Temperature (
oC) Pressure (bar)
Air (Oxygen) 173 mL/min 20 1
Media 1728 37 1
Trypsin 1000 20 1
Phase 5 Volume (mL) Temperature (
oC) Pressure (bar)
Air (Oxygen) 2.07 L/min 20 1
Media 20736 37 1


















Cells In 3.14 x 10
9
Neural Stem Cells Out 6.27 x 10
10
Conversion 0.8
Total Volume (L) 200
Residence Time (hrs) 168
Glucose Consumption Rate (g/(cell*hr)) 2.15 x 10
-10
Hot Water Flow Rate (L/hr) 4.87
Material of Contruction Stainless Steel





O2 Concentration (%) 20
Liquid Volume (L) 52.725
pH 7.2
Reactor Process Variables
Total Sparger Contact Area (mm2) 33.35
Number of Holes 30
Diameter per Hole  (mm) 1.190




Liquid Level Fraction 0.625
Volume of Tank (m3) 0.1
Liquid Volume (L) 52.7
Material of Construction Stainless Steel
Inactivation Chamber Specification Table
 
 

















Formaldehyde Concentration (g/L) 0.2
Residence Time (hrs) 2.0
Liquid Density (kg/m3) 1200
Gas Density (kg/m3) 1.38
  Formaldehyde Amount (L) 39.25
Inactivation Chamber Process Variables
Product Cryostorage Container MIDSCI 24K Cryostorage
Capacity (1 mL vials) 24050
Liquid N2 Capacity  (l) 365
Holding  time (days) 52
Diameter (m) 0.956
Height (m) 1.11
Refigerator Storage Volume (m3) 45.31






Dewar Volume (liters) 1.00
 Liquid Nitrogen Storage Tank
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BATCH SHEET NO.  
PRODUCT Main simulation 
SPD Case File H:\Spring Design\Main simulation.spf 






The following procedures/operations must be performed in order. 
 
             
 
P-4 ( in TFR-101 ) 
             
 
Repeat the following operations 1 time(s). 
 
CHARGE-1:  











Charge 0.00 kg (or 0.00 L) via Port S-103 to TFR-101. 
 
Comments 
      
 0.00 0.25   
CHARGE-2:  
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Charge 0.00 kg (or 0.00 L) via Port S-106 to TFR-101. 
 
Comments 
      
 0.25 0.50   
REACT-1:  











Allow the mixture to react in TFR-101. The exit 
temperature should not exceed 37.0 °C and the exit 
pressure 1.0 bar. Make sure that the final working vessel 
volume does not exceed the maximum allowable working 
to vessel volume ratio (90.0 %). 
 
Comments 
      
 0.50 84.50   
TRANSFER-OUT-1:  











Transfer 0.00 kg (0.00 L) of material out of TFR-101 into 
TFR-102 at a rate of  600.00 kg/h (604.16 L/h). Make sure 
that the final working vessel volume does not exceed the 




      
 84.50 84.75   
 
             
 
P-2 ( in BR-102 ) 
             
 
Repeat the following operations 1 time(s). 
 
 
















Charge 20.81 kg (or 20.78 L) via Port Expanision Media 
Feed to BR-102. 
 
Comments 
      
 0.00 0.31   
HEAT-1:  











Heat the contents of BR-102 for 30.98 min to a final 
temperature of 37.00 °C.  
 
Comments 
      
 0.31 0.91   
TRANSFER-OUT-1:  











Transfer 20.81 kg (21.01 L) of material out of BR-102 into 
SBR-101 at a rate of  297.09 kg/h (300.00 L/h). Make sure 
that the final working vessel volume does not exceed the 




      
 0.91 1.23   
CHARGE-2:  
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Heat the contents of BR-102 for 30.99 min to a final 
temperature of 37.00 °C.  
 
Comments 

















Transfer 52.33 kg (52.84 L) of material out of BR-102 into 
BR-101 at a rate of  600.00 kg/h (605.85 L/h). Make sure 
that the final working vessel volume does not exceed the 










             
 
P-5 ( in TFR-102 ) 
             
 



















Charge 0.01 kg (or 0.01 L) via Port S-107 to TFR-102. 
 
Comments 
      
 84.75 85.00   
PULL-IN-1:  











Transfer 0.00 kg (0.00 L) of material into TFR-102 from 
Source Equipment via … at a rate of  600.00 kg/h (604.16 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (90.0 %). 
 
Comments 
      
 85.00 85.25   
REACT-1:  











Allow the mixture to react in TFR-102. The exit 
temperature should not exceed 37.0 °C and the exit 
pressure 1.2 bar. Make sure that the final working vessel 
volume does not exceed the maximum allowable working 
to vessel volume ratio (90.0 %). 
 
Comments 
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Transfer 0.01 kg (0.01 L) of material out of TFR-102 into 
CF-102 at a rate of  600.00 kg/h (605.17 L/h). Make sure 
that the final working vessel volume does not exceed the 










             
 
P-7 ( in CF-102 ) 
             
 
Repeat the following operations 1 time(s). 
 
CENTRIFUGE-1:  











Centrifuge in CF-102 at a rate of 0.41 L/h for 2.00 min.    
 
Comments 






             
 
P-8 ( in SFR-101 ) 
             
 
Repeat the following operations 1 time(s). 
 
 
















Charge 0.14 kg (or 0.14 L) via Port Ex media to SFR-101. 
 
Comments 

















Transfer 0.00 kg (0.00 L) of material into SFR-101 from 
Source Equipment via … at a rate of  600.00 kg/h (592.53 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (90.0 %). 
 
Comments 

















Feed  SFR-101 via Port Stream Name from Source 
Equipment. Allow the mixture to react. The exit 
temperature should not exceed 37.00 °C and the exit 
pressure 1.01 bar. Make sure that the vessel volume 
does not exceed 7.27 % of the total vessel volume. 
 
Comments 
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Transfer 0.14 kg (0.14 L) of material out of SFR-101 into 
CF-103 at a rate of  600.00 kg/h (605.55 L/h). Make sure 
that the final working vessel volume does not exceed the 










             
 
P-9 ( in CF-103 ) 
             
 
Repeat the following operations 1 time(s). 
 
CENTRIFUGE-1:  











Centrifuge in CF-103 at a rate of 1.75 L/h for 5.00 min.    
 
Comments 






             
 
P-10 ( in SFR-102 ) 
             
 
Repeat the following operations 1 time(s). 
 
 
















Charge 1.72 kg (or 1.73 L) via Port Ex media 2 to SFR-102. 
 
Comments 

















Transfer 0.00 kg (0.00 L) of material into SFR-102 from 
Source Equipment via … at a rate of  600.00 kg/h (599.75 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (90.0 %). 
 
Comments 

















Feed  SFR-102 via Port Stream Name from Source 
Equipment. Allow the mixture to react. The exit 
temperature should not exceed 37.00 °C and the exit 
pressure 1.79 bar. Make sure that the vessel volume 
does not exceed 43.61 % of the total vessel volume. 
 
Comments 
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Transfer 1.98 kg (1.99 L) of material out of SFR-102 into 
CF-104 at a rate of  600.00 kg/h (605.61 L/h). Make sure 
that the final working vessel volume does not exceed the 










             
 
P-11 ( in CF-104 ) 
             
 
Repeat the following operations 1 time(s). 
 
CENTRIFUGE-1:  











Centrifuge in CF-104 at a rate of 23.98 L/h for 5.00 min.    
 
Comments 






             
 
P-1 ( in SBR-101 ) 
             
 
Repeat the following operations 1 time(s). 
 
 
















Transfer 20.81 kg (21.01 L) of material into SBR-101 from 
Source Equipment via … at a rate of  600.00 kg/h (605.85 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (50.0 %). 
 
Comments 

















Transfer 0.09 kg (0.09 L) of material into SBR-101 from 
Source Equipment via … at a rate of  300.00 kg/h (300.52 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (50.0 %). 
 
Comments 

















Feed  SBR-101 via Port Stream Name from Source 
Equipment. Allow the mixture to react. The exit 
temperature should not exceed 37.00 °C and the exit 
pressure 1.01 bar. Make sure that the vessel volume 
does not exceed 49.98 % of the total vessel volume. 
 
Comments 
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Transfer 20.92 kg (21.12 L) of material out of SBR-101 
into CF-101 at a rate of  100.00 kg/h (100.97 L/h). Make 
sure that the final working vessel volume does not 
exceed the maximum allowable working to vessel volume 
ratio (90.0 %). 
 
Comments 






             
 
P-3 ( in CF-101 ) 
             
 
Repeat the following operations 1 time(s). 
 
CENTRIFUGE-1:  











Centrifuge in CF-101 at a rate of 84.49 L/h for 5.00 min.    
 
Comments 






             
 
P-6 ( in BR-101 ) 
             
 
Repeat the following operations 1 time(s). 
 
 
















Transfer 52.33 kg (52.84 L) of material into BR-101 from 
Source Equipment via … at a rate of  600.00 kg/h (605.85 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (90.0 %). 
 
Comments 

















Transfer 0.24 kg (0.24 L) of material into BR-101 from 
Source Equipment via … at a rate of  600.00 kg/h (603.02 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (50.0 %). 
 
Comments 

















Feed  BR-101 via Port Stream Name from Source 
Equipment. Allow the mixture to react. The exit 
temperature should not exceed 37.00 °C and the exit 
pressure 1.01 bar. Make sure that the vessel volume 
does not exceed 49.88 % of the total vessel volume. 
 
Comments 
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Transfer 52.72 kg (53.21 L) of material out of BR-101 into 
CS-105 at a rate of  600.00 kg/h (605.59 L/h). Make sure 
that the final working vessel volume does not exceed the 










             
 
P-12 ( in CS-105 ) 
             
 
Repeat the following operations 1 time(s). 
 
CENTRIFUGE-1:  











Centrifuge in CS-105 at a rate of 13.30 L/h for 240.00 
min.    
 
Comments 






             
 
P-13 ( in FT-101 ) 
             
 
Repeat the following operations 1 time(s). 
 
 
















Transfer 5.29 kg (5.32 L) of material into FT-101 from 
Source Equipment via … at a rate of  600.00 kg/h (603.22 
L/h). Make sure that the final working vessel volume 
does not exceed the maximum allowable working to 
vessel volume ratio (99.0 %). 
 
Comments 

















Freeze the contents of FT-101 for 117.00 min to a final 
temperature of -80.00 °C.  
 
Comments 

















Transfer 5.29 kg (5.10 L) of material out of FT-101 into 
Target Equipment at a rate of  600.00 kg/h (578.50 L/h). 
Make sure that the final working vessel volume does not 
exceed the maximum allowable working to vessel volume 
ratio (99.0 %). 
 
Comments 
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Key Equations  
Material and Energy Balance  
𝐼𝑛 − 𝑂𝑢𝑡 + 𝐺𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 = 𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑄 = 𝑚𝐶𝑝∆𝑇 
























𝑜(𝐵1 + 𝐵2𝐹𝑚𝐹𝑝) 
𝐹𝑝 =
(𝑃 + 1)𝐷




𝐹𝑇 = 1 + 0.00184∆𝑇 − 0.00000335(∆𝑇)
2 
𝐶𝑇𝑚 = 1.18𝐶𝐵𝑚 
Boiler 
𝑄 = 𝑚𝐶𝑝∆𝑇 + 𝑚𝜆 


















Ao = Total Area of Holes (m
2) 
ΔP = Pressure Drop (Pa) 
V = Velocity of the Fluid (m/s) 







f = Friction Factor 
D = Diameter (m) 
Ek = Kinetic Energy (J) 







ρ = Density of Fluid (kg/m3) 
V = Velocity of the Fluid (m/s) 
D = Diameter (m) 
Ek = Kinetic Energy (J) 
 
 








ρ = Density of Fluid (kg/m3) 
V = Velocity of the Fluid (m/s) 
D = Diameter of the Pipe (m) 
μ = Dynamic Viscosity of the Fluid (kg/s/m)  
Re = Reynolds Number 
 




N = Number of Cells 
No = Initial Number of Cells 
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Material Safety Data Sheet 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product Name Formaldehyde 37% Solution 
Cat No. 9300-1, 9300-5, 9300-55, 9311, 9315, C4320, C4320-5 
Synonyms No information available. 
Recommended Use Laboratory chemicals 
2. HAZARDS IDENTIFICATION 
Target Organs Gastrointestinal tract (GI), Central nervous system (CNS), Eyes, Respiratory system, Skin, 
Optic nerve, Liver, Kidney, spleen, Blood 
Potential Health Effects 
Acute Effects 
Principle Routes of Exposure 
Eyes Causes burns. 
Skin Toxic in contact with skin. Causes burns. May produce an allergic reaction. 
Inhalation Vapor harmful. Toxic by inhalation. Causes burns. 
Ingestion May be fatal or cause blindness if swallowed. Ingestion may cause gastrointestinal irritation, 
nausea, vomiting and diarrhea. May cause burns to the digestive tract. 
Chronic Effects May cause cancer. Tumorigenic effects have been reported in experimental animals.. 
Experiments have shown reproductive toxicity effects on laboratory animals. May cause 
adverse liver effects. May cause adverse kidney effects. Repeated contact may cause allergic 
reactions in very susceptible persons. Danger of very serious irreversible effects. 
See Section 11 for additional Toxicological information. 
____________________________________________________________________________________
_________ 
Page 1 / 10 
Emergency Telephone Number 
Chemtrec US: (800) 424-9300 
Chemtrec EU: (202) 483-7616 
Emergency Overview 
Revision Number 1 
Flammable liquid and vapor. Cancer hazard. Poison, may be fatal or cause blindness if swallowed. 
Cannot be made nonpoisonous. 
Vapor harmful. Toxic by inhalation, in contact with skin and if swallowed. Causes burns by all exposure 
routes. May cause an allergic skin reaction. Danger of very serious irreversible effects. 
Creation Date 17-Mar-2010 Revision Date 17-Mar-2010 
Company 
Richard Allan Scientific 
A Subsidiary of Thermo Fisher Scientific 
4481 Campus Drive 
Kalamazoo, MI 49008 
Tel: (800) 522-7270 
DANGER! 
Appearance Colorless Physical State Liquid odor pungent 
____________________________________________________________________________________
_________ 
Aggravated Medical Conditions Central nervous system disorders. Gastrointestinal tract. Preexisting eye disorders. 
Skin 
disorders. 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Haz/Non-haz 
Component CAS-No Weight % 
Water 7732-18-5 48 - 53 
Buffers NA - 
Formaldehyde 50-00-0 37 - 38 
Methyl alcohol 67-56-1 10 - 15 
4. FIRST AID MEASURES 
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Eye Contact Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. 
Immediate medical attention is required. 
Skin Contact Wash off immediately with plenty of water for at least 15 minutes. Immediate medical attention 
is required. 
Inhalation Move to fresh air. If breathing is difficult, give oxygen. Do not use mouth-to-mouth resuscitation 
if victim ingested or inhaled the substance; induce artificial respiration with a respiratory 
medical device. Immediate medical attention is required. 
Ingestion Do not induce vomiting. Call a physician or Poison Control Center immediately. 
Notes to Physician Treat symptomatically. 
5. FIRE-FIGHTING MEASURES 
Flash Point 60°C / 140°F 
Method No information available. 
Autoignition Temperature 430°C / 806°F 
Explosion Limits 
Upper 73 vol % 
Lower 7 vol % 
Suitable Extinguishing Media Use water spray, alcohol-resistant foam, dry chemical or carbon 
dioxide. 
Unsuitable Extinguishing Media No information available. 
Hazardous Combustion Products No information available. 
Sensitivity to mechanical impact No information available. 
Sensitivity to static discharge No information available. 
Specific Hazards Arising from the Chemical 
Flammable. Risk of ignition. Vapors may form explosive mixtures with air. Vapors may travel to source of ignition and 
flash back. 
Containers may explode when heated. 
____________________________________________________________________________________
_________ 
Page 2 / 10 
Thermo Fisher Scientific - Formaldehyde 37% Solution Revision Date 17-Mar-2010 
____________________________________________________________________________________
_________ 
Protective Equipment and Precautions for Firefighters 
As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) 
and full protective 
gear. Thermal decomposition can lead to release of irritating gases and vapors. 
6. ACCIDENTAL RELEASE MEASURES 
Personal Precautions Use personal protective equipment. Remove all sources of ignition. Take precautionary 
measures against static discharges. Do not get in eyes, on skin, or on clothing. 
Environmental Precautions Should not be released into the environment. 
Methods for Containment and Clean 
Up 
Remove all sources of ignition. Soak up with inert absorbent material. Take precautionary 
measures against static discharges. Keep in suitable and closed containers for disposal. 
7. HANDLING AND STORAGE 
Handling Use only under a chemical fume hood. Use explosion-proof equipment. Wear personal 
protective equipment. Keep away from open flames, hot surfaces and sources of ignition. Take 
precautionary measures against static discharges. Do not breathe vapors or spray mist. Do not 
get in eyes, on skin, or on clothing. 
Storage Keep containers tightly closed in a dry, cool and well-ventilated place. Keep away from heat 
and sources of ignition. Flammables area. 
8. EXPOSURE CONTROLS / PERSONAL PROTECTION 
Engineering Measures Use only under a chemical fume hood. Use explosion-proof 
electrical/ventilating/lighting/equipment. Ensure that eyewash stations and safety showers are 
close to the workstation location. 
Exposure Guidelines 
Component ACGIH TLV OSHA PEL NIOSH IDLH 
Formaldehyde Ceiling: 0.3 ppm (Vacated) TWA: 3 ppm 
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(Vacated) STEL: 10 ppm 
(Vacated) Ceiling: 5 ppm 
TWA: 0.75 ppm 
STEL: 2 ppm 
IDLH: 20 ppm 
TWA: 0.016 ppm 
Ceiling: 0.1 ppm 
Methyl alcohol TWA: 200 ppm 
STEL: 250 ppm 
Skin 
(Vacated) TWA: 200 ppm 
(Vacated) TWA: 260 mg/m3 
(Vacated) STEL: 325 mg/m3 
(Vacated) STEL: 250 ppm 
Skin 
TWA: 200 ppm 
TWA: 260 mg/m3 
IDLH: 6000 ppm 
TWA: 200 ppm 
TWA: 260 mg/m3 
STEL: 250 ppm 
STEL: 325 mg/m3 
Component Quebec Mexico OEL (TWA) Ontario TWAEV 
Formaldehyde Ceiling: 3 mg/m3 
Ceiling: 2 ppm 
Peak: 3 mg/m3 
Peak: 2 ppm 
STEL: 1.0 ppm 
CEV: 1.5 ppm 
____________________________________________________________________________________
_________ 
Page 3 / 10 
Revision Date 17-Mar-2010 
NFPA Health 3 Flammability 2 
Thermo Fisher Scientific - Formaldehyde 37% Solution 
Instability 0 Physical hazards N/A 
____________________________________________________________________________________
_________ 
Component Quebec Mexico OEL (TWA) Ontario TWAEV 
Methyl alcohol TWA: 200 ppm 
TWA: 262 mg/m3 
STEL: 328 mg/m3 
STEL: 250 ppm 
Skin 
TWA: 200 ppm 
TWA: 260 mg/m3 
STEL: 250 ppm 
STEL: 310 mg/m3 
TWA: 200 ppm 
TWA: 260 mg/m3 
STEL: 325 mg/m3 
STEL: 250 ppm 
Skin 
NIOSH IDLH: Immediately Dangerous to Life or Health 
Personal Protective Equipment 
Eye/face Protection Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's 
eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166 
Skin and body protection Wear appropriate protective gloves and clothing to prevent skin exposure 
Respiratory Protection Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard 
EN 
149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits 
are exceeded or if irritation or other symptoms are experienced 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Physical State Liquid 
 
 





Odor Threshold No information available. 
pH 2.8 - 4.0 
Vapor Pressure 6768 mmHg @ 20 °C 
Vapor Density 1.01 
Viscosity No information available. 
Boiling Point/Range 96.1 - 101°C / 205 - 213.8°F 
Melting Point/Range 0°C / 32°F 
Decomposition temperature °C No information available. 
Flash Point 60°C / 140°F 
Evaporation Rate No information available. 
Specific Gravity 1.0749 - 1.2020 
Solubility Soluble in water 
log Pow No data available 
10. STABILITY AND REACTIVITY 
Stability Stable under normal conditions. 
Conditions to Avoid Incompatible products. Heat, flames and sparks. 
Incompatible Materials Strong oxidizing agents, Strong bases, Acids, Acid anhydrides, Acid 
chlorides, Metals, Peroxides 
Hazardous Decomposition Products Carbon monoxide (CO), Formaldehyde, Methanol 
Hazardous Polymerization Hazardous polymerization does not occur 
Hazardous Reactions . None under normal processing. 
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Product Information No acute toxicity information is available for this product 
Component Information 
Component LD50 Oral LD50 Dermal LC50 Inhalation 
Water 90 mL/kg ( Rat ) Not listed Not listed 
Formaldehyde 500 mg/kg ( Rat ) Not listed 0.578 mg/L ( Rat ) 4 h 
Methyl alcohol 5628 mg/kg ( Rat ) 15800 mg/kg ( Rabbit ) 64000 ppm ( Rat ) 4 h 
83.2 mg/L ( Rat ) 4 h 
Irritation Causes burns by all exposure routes 
Toxicologically Synergistic 
Products 
No information available. 
Chronic Toxicity 
Carcinogenicity The table below indicates whether each agency has listed any ingredient as a carcinogen. 
Component ACGIH IARC NTP OSHA Mexico 
Formaldehyde A2 Group 1 Reasonably Anticipated X Not listed 
ACGIH: (American Conference of Governmental Industrial Hygienists) 
A1 - Known Human Carcinogen 
A2 - Suspected Human Carcinogen 
A3 - Animal Carcinogen 
ACGIH: (American Conference of Governmental Industrial Hygienists) 
IARC: (International Agency for Research on Cancer) 
IARC: (International Agency for Research on Cancer) 
Group 1 - Carcinogenic to Humans 
Group 2A - Probably Carcinogenic to Humans 
Group 2B - Possibly Carcinogenic to Humans 
NTP: (National Toxicity Program) 
NTP: (National Toxicity Program) 
Known - Known Carcinogen 
Reasonably Anticipated - Reasonably Anticipated to be a Human Carcinogen 
Sensitization May cause sensitization by skin contact 
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Mutagenic Effects Mutagenic effects have occurred in humans. 
Reproductive Effects Experiments have shown reproductive toxicity effects on laboratory animals. 
Developmental Effects Developmental effects have occurred in experimental animals. 
Teratogenicity Teratogenic effects have occurred in experimental animals.. 
Other Adverse Effects Tumorigenic effects have been reported in experimental animals.. See actual entry in 
RTECS 
for complete information. 
Endocrine Disruptor Information No information available 
12. ECOLOGICAL INFORMATION 
____________________________________________________________________________________
_________ 
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12. ECOLOGICAL INFORMATION 
Ecotoxicity 
. 
Component Freshwater Algae Freshwater Fish Microtox Water Flea 
Formaldehyde Not listed Leuciscus idus: LC50 = 15 
mg/L 96h 
Not listed EC50 = 20 mg/L 96h 
EC50 = 2 mg/L 48h 
Methyl alcohol Not listed Pimephales promelas: LC50 
> 10000 mg/L 96h 
EC50 = 39000 mg/L 25 min 
EC50 = 40000 mg/L 15 min 
EC50 = 43000 mg/L 5 min 
EC50 > 10000 mg/L 24h 
Persistence and Degradability No information available 
Bioaccumulation/ Accumulation No information available 
Mobility . 
Component log Pow 
Water -1.87 
Formaldehyde 0.35 
Methyl alcohol -0.74 
13. DISPOSAL CONSIDERATIONS 
Waste Disposal Methods Chemical waste generators must determine whether a discarded chemical is classified as 
a 
hazardous waste. Chemical waste generators must also consult local, regional, and national 
hazardous waste regulations to ensure complete and accurate classification 
Component RCRA - U Series Wastes RCRA - P Series Wastes 
Formaldehyde - 50-00-0 U122 - 
Methyl alcohol - 67-56-1 U154 - 
14. TRANSPORT INFORMATION 
DOT 
UN-No UN1198 
Proper Shipping Name FORMALDEHYDE, SOLUTIONS, FLAMMABLE 
Hazard Class 3 
Subsidiary Hazard Class 8 
Packing Group III 
TDG 
UN-No UN1198 
Proper Shipping Name FORMALDEHYDE, SOLUTIONS, FLAMMABLE 
Hazard Class 3 
Subsidiary Hazard Class 8 
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14. TRANSPORT INFORMATION 
IATA 
UN-No UN1198 
Proper Shipping Name FORMALDEHYDE, SOLUTIONS, FLAMMABLE 
Hazard Class 3 
Subsidiary Hazard Class 8 
Packing Group III 
IMDG/IMO 
UN-No UN1198 
Proper Shipping Name FORMALDEHYDE, SOLUTIONS, FLAMMABLE 
Hazard Class 3 
Subsidiary Hazard Class 8 
Packing Group III 
15. REGULATORY INFORMATION 
International Inventories 
Component TSCA DSL NDSL EINECS ELINCS NLP PICCS ENCS AICS CHINA KECL 
Water X X - 231-791- 
2 
- X - X X KE- 
35400 
X 
Formaldehyde X X - 200-001- 
8 
- X X X X KE- 
17074 
X 
Methyl alcohol X X - 200-659- 
6 




X - Listed 
E - Indicates a substance that is the subject of a Section 5(e) Consent order under TSCA. 
F - Indicates a substance that is the subject of a Section 5(f) Rule under TSCA. 
N - Indicates a polymeric substance containing no free-radical initiator in its inventory name but is considered to cover the 
designated 
polymer made with any free-radical initiator regardless of the amount used. 
P - Indicates a commenced PMN substance 
R - Indicates a substance that is the subject of a Section 6 risk management rule under TSCA. 
S - Indicates a substance that is identified in a proposed or final Significant New Use Rule 
T - Indicates a substance that is the subject of a Section 4 test rule under TSCA. 
XU - Indicates a substance exempt from reporting under the Inventory Update Rule, i.e. Partial Updating of the TSCA 
Inventory Data Base 
Production and Site Reports (40 CFR 710(B). 
Y1 - Indicates an exempt polymer that has a number-average molecular weight of 1,000 or greater. 
Y2 - Indicates an exempt polymer that is a polyester and is made only from reactants included in a specified list of low 
concern reactants that 
comprises one of the eligibility criteria for the exemption rule. 
U.S. Federal Regulations 
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Component CAS-No Weight % SARA 313 - Threshold 
Values % 
Formaldehyde 50-00-0 37 - 38 0.1 
Methyl alcohol 67-56-1 10 - 15 1.0 
SARA 311/312 Hazardous Categorization 
Acute Health Hazard No 
Chronic Health Hazard No 
Fire Hazard Yes 
Sudden Release of Pressure Hazard No 
Reactive Hazard No 
Clean Water Act 
Component CWA - Hazardous 
Substances 
CWA - Reportable 
Quantities 
CWA - Toxic Pollutants CWA - Priority Pollutants 
Formaldehyde X 100 lb - - 
Clean Air Act 
Component HAPS Data Class 1 Ozone Depletors Class 2 Ozone Depletors 
Formaldehyde X - 
Methyl alcohol X - 
OSHA 
Component Specifically Regulated Chemicals Highly Hazardous Chemicals 
Formaldehyde 0.5 ppm Action Level 
0.75 ppm TWA 
2 ppm STEL 
TQ: 1000 lb 
CERCLA 
This material, as supplied, contains one or more substances regulated as a hazardous substance under the 
Comprehensive 
Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) 
Component Hazardous Substances RQs CERCLA EHS RQs 
Formaldehyde 100 lb 100 lb 
Methyl alcohol 5000 lb - 
California Proposition 65 
This product contains the following Proposition 65 chemicals: 
Component CAS-No California Prop. 65 Prop 65 NSRL 
Formaldehyde 50-00-0 Carcinogen 40 μg/day 
State Right-to-Know 
Component Massachusetts New Jersey Pennsylvania Illinois Rhode Island 
Formaldehyde X X X X X 
____________________________________________________________________________________
_________ 
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Component Massachusetts New Jersey Pennsylvania Illinois Rhode Island 
Methyl alcohol X X X X X 
U.S. Department of Transportation 
Reportable Quantity (RQ): Y 
DOT Marine Pollutant N 
DOT Severe Marine Pollutant N 
U.S. Department of Homeland Security 
This product contains the following DHS chemicals: 
Component DHS Chemical Facility Anti-Terrorism Standard 
Formaldehyde 11250 lb STQ (solution) 
Other International Regulations 
Mexico - Grade Moderate risk, Grade 2 
 
 




This product has been classified in accordance with the hazard criteria of the Controlled Products 
Regulations (CPR) and the 
MSDS contains all the information required by the CPR. 
WHMIS Hazard Class 
B3 Combustible liquid 
D1B Toxic materials 
D2A Very toxic materials 
D2B Toxic materials 
E Corrosive material 
16. OTHER INFORMATION 
Prepared By Regulatory Affairs 
Thermo Fisher Scientific 
Tel: (412) 490-8929 
Creation Date 17-Mar-2010 
Print Date 17-Mar-2010 
Revision Summary "***", and red text indicates revision 
____________________________________________________________________________________
_________ 
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The information provided on this Safety Data Sheet is correct to the best of our knowledge, information and 
belief at the date 
of its publication. The information given is designed only as a guide for safe handling, use, processing, 
storage, 
transportation, disposal and release and is not to be considered as a warranty or quality specification. The 
information 
relates only to the specific material designated and may not be valid for such material used in combination 
with any other 
material or in any process, unless specified in the text. 
End of MSDS 
____________________________________________________________________________________
_________ 
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Safety Data Sheet 
GHS - Classification 
Precautionary Statements 
P210 - Keep away from heat/sparks/open flames/hot surfaces. - No smoking 
P280 - Wear protective gloves/protective clothing/eye protection/face protection 
P370 + P378 - In case of fire, use water/water spray/water jet/carbon dioxide/sand/foam/alcohol resistant 






H227 - Combustible liquid 
SECTION 2: Hazards identification 
Product code D12345 
Company/undertaking identification 
Physical hazards 
Country specific Emergency Number (if available): 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
GHS Physical Hazard 1 Flammable liquids 
Product name DMSO (dimethylsulfoxide), anhydrous 
_________________________________________________________________________________________________________
_______ 
GHS Physical Hazard Category Number Category 4 
For research use only. Not intended for human or animal diagnostic or therapeutic uses. 
D12345 
Identification of the substance or mixture 
Revision date 
Product name DMSO (dimethylsulfoxide), anhydrous 
Page 1 / 6 
24 hour Emergency Response: 866-536-0631 
301-431-8585 





5250 Mainway Drive 
Burlington, ONT 




5791 Van Allen Way 
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PO Box 6482 
Carlsbad, CA 92008 
+1 760 603 7200 
CHEMTREC Brazil (Rio De Janeiro) 
inhalation Remove to fresh air. If symptoms persist, call a physician. If not breathing, give 
artificial respiration. 
Notes to Physician Treat symptomatically. 
eyes 
SECTION 5: Firefighting measures 
Target Organ Effects No known effects under normal use conditions. 
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical. 
Mild eye irritation. 
Special protective equipment for firefighters Wear self-contained breathing apparatus and protective 
suit. 
Carcinogenic effects None. 
SECTION 6: Accidental release measures 
Principle Routes of Exposure 
Potential Health Effects 
HMIS 
Personal precautions ELIMINATE all ignition sources (no smoking, flares, sparks or flames in immediate 
area). Use personal protection equipment. 
Methods for cleaning up Soak up with inert absorbent material. Sweep up and shovel into suitable 
containers for disposal. After cleaning, flush away traces with water. 
Mutagenic effects None. 
Skin 
Reproductive toxicity 
SECTION 4: First aid measures 
None. 
Mild skin irritation. Components of the product may be absorbed into the body 
through the skin. 
Skin contact Wash off immediately with plenty of water. If symptoms occur, obtain medical 
advice. 
Sensitization 
Eye contact Rinse immediately with plenty of water, also under the eyelids, for at least 15 
minutes. Consult a physician if necessary. 
No sensitization responses were observed. 
Ingestion Never give anything by mouth to an unconscious person. If symptoms persist, call 











Product name DMSO (dimethylsulfoxide), anhydrous 
Page 2 / 6 
We recommend handling all chemicals with caution. 
31-Jul-2015 










Odor No data available 
Odor Threshold No data available 
Storage 
Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment. 
Keep away from heat, sparks, flame and other sources of ignition (i.e., pilot lights, 
electric motors and static electricity). Do not store near combustible materials. 
Keep in properly labeled containers. 
Chemical Name OSHA PEL OSHA PEL (Ceiling) ACGIH OEL (TWA) ACGIH OEL (STEL) 
Hand protection Impervious butyl rubber gloves. Nitrile gloves are not recommended. Some brands 
of Nitrile gloves have breakthrough times of five minutes. 
SECTION 7: Handling and storage 
See Section 12 for more information. 
Eye protection Wear safety glasses with side shields (or goggles). 
dimethylsulfoxide None 
Skin and Body Protection Lightweight protective clothing. 
None None 
Hygiene measures Handle in accordance with good industrial hygiene and safety practice. 
None 
Oxidizing properties No information available 
Water solubility miscible 
Environmental exposure 
controls 
Upper explosion limit 61% - 64% 
Prevent product from entering drains. 
Lower explosion limit 2.4% - 2.8% 
SECTION 8: Exposure controls/personal protection 
Engineering measures Ensure adequate ventilation, especially in confined areas. 





Personal Protective Equipment 




Personal Protective Equipment requirements are dependent on the user institution's risk assessment and 
are specific 
to the risk assessment for each laboratory where this material may be used. 
Prevent further leakage or spillage if safe to do so. 
D12345 
Appearance No information available 
Revision date 
°C 188 - 190 
Product name DMSO (dimethylsulfoxide), anhydrous 
°F 64.4 - 66.2 
Page 3 / 6 
°F 417.2 - 420.8 
Melting point / melting range °C 18 - 19 
Autoignition Temperature 
31-Jul-2015 
°C 87 - 89 
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°F 370 - 374 
flash point 
Product code 
°C 214 - 216 
°F 188.6 - 192.2 
Hazardous decomposition products formed under fire conditions. Sulphur oxides. 
Carbon oxides. 
Sensitization No sensitization responses were observed. 
SECTION 10: Stability and reactivity 
polymerization 
Chemical Name LD50 (oral,rat/mouse) LD50 (dermal,rat/rabbit) 
SECTION 12: Ecological information 
LC50 (inhalation,rat/mouse) 
Hazardous polymerization does not occur. 
dimethylsulfoxide 
Ecotoxicity Contains no substances known to be hazardous to the environment or not 
degradable in waste water treatment plants. 
14500 mg/kg Oral LD50 >40000 mg/kg bw 
Mobility completely soluble. 
>5000 mg/l 
Biodegradation Inherently biodegradable. 
Bioaccumulation Material does not bioaccumulate. 
Principle Routes of Exposure 
Potential Health Effects 
Chemical Name Freshwater Algae 
Data 
Water Flea Data Freshwater Fish 
Species Data 
Microtox Data log Pow 
SECTION 11: Toxicological information 
dimethylsulfoxide logPow-2.03 
Viscosity 
eyes Mild eye irritation. 
Stability 
SECTION 13: Disposal considerations 
Skin Mild skin irritation. Components of the product may be absorbed into the body 
through the skin. 
Dispose of contents/containers in accordance with local regulations. 




No information available. 
PH Range 
Acute Toxicity 
Ingestion No information available. 
Materials to avoid 
D12345 
Strong acids. Strong oxidizing agents. 
Revision date 
Carcinogenic effects 
Product name DMSO (dimethylsulfoxide), anhydrous 
None. 















Reproductive toxicity None. 
IATA 
For research use only. Not intended for human or animal diagnostic or therapeutic uses. 
Packing group None 
SECTION 14: Transport information 
UN-No none 
Proper Shipping Name No dangerous good in sense of these transport regulations 
SECTION 16: Other information 
Hazard Class None 
Subsidiary class 




Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61) 
This product does not contains HAPs. 
California Proposition 65 
This product does not contain any Proposition 65 chemicals. 
US Federal Regulations 
WHMIS Hazard Class 
B3 - Combustible liquid 




67-68-5 ( 95-100 ) 
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) 
and the 
MSDS contains all the information required by the CPR. 
US State Regulations 
Listed 
SARA 313 





Massachusetts - RTK 
Product name DMSO (dimethylsulfoxide), anhydrous 
New Jersey - RTK 
Page 5 / 6 









"The above information was acquired by diligent search and/or investigation and the recommendations 
are based on 
prudent application of professional judgment. The information shall not be taken as being all inclusive and 
is to be 
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used only as a guide. All materials and mixtures may present unknown hazards and should be used with 
caution. 
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall 
not be held 
liable for any damages or losses resulting from the handling or from contact with the product as described 
herein. 
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR 
IMPLIED, 
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY 
PARTICULAR PUPOSE" 
Revision date 31-Jul-2015 
Product code Product name DMSO (dimethylsulfoxide), anhydrous 
www.lifetechnologies.com 
End of Safety Data Sheet 
D12345 
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Ethylenediamine Tetraacetic Acid, Disodium Salt 
Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, disodium salt, dihydrate; 
Ethylenediaminetetraacetic acid disodium salt dihydrate; Ethylenediamine tetraacetic 
acid disodiumsalt dihydrate; Disodium edetate dihydrate; Glycine, N,N'-1,2-ethanedlylbis 
[N-(carboxymethyl), disodium salt, dihydrate; Disodium dihydrogen ethylenediamine-N,N, 
N',N'-tetraacetate, dihydrate; EDTA, disodium, dihydrate; Ethylene diamine tetraacetic 
acid, disodium salt; Disodium EDTA, dihydrate; Acetic acid, (ethylenedinitrilo)tetra-, 
disodium salt, dihydrate 
Powder. 
CHEMTREC: 800.424.9300 
Outside US: 703.527.3887 
SAFETY DATA SHEET 
GHS product identifier 
Other means of identification 
Product type 
Emergency telephone 
number (with hours of 
operation) 




Chemical name : Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2) 
Supplier's details : Thermo Fisher Scientific 
Pierce Biotechnology 
P.O. Box 117 




7 AM - 5 PM Central Time (GMT -06:00) 
Ethylenediamine Tetraacetic Acid, Disodium Salt 




















Section 2. Hazards identification 
Classification of the Not classified. 
substance or mixture 
: 
Signal word : No signal word. 
Hazard statements : No known significant effects or critical hazards. 
Precautionary statements 
Prevention : Not applicable. 
Response : Not applicable. 
Storage : Not applicable. 
Disposal : Not applicable. 
GHS label elements 
OSHA/HCS status : While this material is not considered hazardous by the OSHA Hazard Communication 
Standard (29 CFR 1910.1200), this MSDS contains valuable information critical to the 
safe handling and proper use of the product. This MSDS should be retained and 
available for employees and other users of this product. 
Hazards not otherwise 
classified 
: Handling and/or processing of this material may generate a dust which can cause 
mechanical irritation of the eyes, skin, nose and throat. 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 1/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 3. Composition/information on ingredients 
Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2: 
2) 
98 - 100 6381-92-6 
Ingredient name % CAS number 
There are no additional ingredients present which, within the current knowledge of the supplier and in 
the 
concentrations applicable, are classified as hazardous to health or the environment and hence require 
reporting in 
this section. 
Chemical name : Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2) 
Other means of 
identification 
: Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, disodium salt, dihydrate; 
Ethylenediaminetetraacetic acid disodium salt dihydrate; Ethylenediamine tetraacetic 
acid disodiumsalt dihydrate; Disodium edetate dihydrate; Glycine, N,N'-1,2-ethanedlylbis 
[N-(carboxymethyl), disodium salt, dihydrate; Disodium dihydrogen ethylenediamine-N,N, 
N',N'-tetraacetate, dihydrate; EDTA, disodium, dihydrate; Ethylene diamine tetraacetic 
acid, disodium salt; Disodium EDTA, dihydrate; Acetic acid, (ethylenedinitrilo)tetra-, 
disodium salt, dihydrate 
CAS number : 6381-92-6 
Substance/mixture 
CAS number/other identifiers 
: 
Occupational exposure limits, if available, are listed in Section 8. 
Substance 
Any concentration shown as a range is to protect confidentiality or is due to batch variation. 
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Wash out mouth with water. Remove victim to fresh air and keep at rest in a position 
comfortable for breathing. If material has been swallowed and the exposed person is 
conscious, give small quantities of water to drink. Do not induce vomiting unless directed 
to do so by medical personnel. Get medical attention if symptoms occur. 
Immediately flush eyes with plenty of water, occasionally lifting the upper and lower 
eyelids. Check for and remove any contact lenses. Get medical attention if irritation 
occurs. 
Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. 
Get medical attention if symptoms occur. 
Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get 
medical attention if symptoms occur. In case of inhalation of decomposition products in 
a fire, symptoms may be delayed. The exposed person may need to be kept under 
medical surveillance for 48 hours. 








Description of necessary first aid measures 
Most important symptoms/effects, acute and delayed 
Inhalation : Exposure to airborne concentrations above statutory or recommended exposure limits 
may cause irritation of the nose, throat and lungs. Exposure to decomposition products 
may cause a health hazard. Serious effects may be delayed following exposure. 
Ingestion : No known significant effects or critical hazards. 
Skin contact : No known significant effects or critical hazards. 
Exposure to airborne concentrations above statutory or recommended exposure limits 
may cause irritation of the eyes. 
Eye contact : 
Over-exposure signs/symptoms 
Skin contact 
Inhalation Adverse symptoms may include the following: 
respiratory tract irritation 
coughing 
No specific data. 
: 
: 
Eye contact : Adverse symptoms may include the following: 
irritation 
redness 
Potential acute health effects 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 2/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 4. First aid measures 
Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training. 
Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The 
exposed person may need to be kept under medical surveillance for 48 hours. 
Specific treatments : No specific treatment. 
Ingestion : No specific data. 
See toxicological information (Section 11) 
Indication of immediate medical attention and special treatment needed, if necessary 
Section 5. Fire-fighting measures 
Promptly isolate the scene by removing all persons from the vicinity of the incident if 
there is a fire. No action shall be taken involving any personal risk or without suitable 
 
 






Specific hazards arising 
from the chemical 





No specific fire or explosion hazard. 
Fire-fighters should wear appropriate protective equipment and self-contained breathing 
apparatus (SCBA) with a full face-piece operated in positive pressure mode. 
Special protective 
equipment for fire-fighters 













Special protective actions 
for fire-fighters 
: 
Section 6. Accidental release measures 
Environmental precautions 
Personal precautions, protective equipment and emergency procedures 
Move containers from spill area. Approach release from upwind. Prevent entry into 
sewers, water courses, basements or confined areas. Vacuum or sweep up material and 
place in a designated, labeled waste container. Avoid creating dusty conditions and 
prevent wind dispersal. Dispose of via a licensed waste disposal contractor. Note: see 
Section 1 for emergency contact information and Section 13 for waste disposal. 
: 
: No action shall be taken involving any personal risk or without suitable training. 
Evacuate surrounding areas. Keep unnecessary and unprotected personnel from 
entering. Do not touch or walk through spilled material. Avoid breathing dust. Put on 
appropriate personal protective equipment. 
Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and 
sewers. Inform the relevant authorities if the product has caused environmental pollution 
(sewers, waterways, soil or air). 
Large spill : 
Move containers from spill area. Vacuum or sweep up material and place in a 
designated, labeled waste container. Dispose of via a licensed waste disposal contractor. 
Small spill : 
Methods and materials for containment and cleaning up 
For non-emergency 
personnel 
For emergency responders : If specialised clothing is required to deal with the spillage, take note of any 
information in 
Section 8 on suitable and unsuitable materials. See also the information in "For nonemergency 
 
 




Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 3/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 7. Handling and storage 
Advice on general 
occupational hygiene 
Conditions for safe storage, 
including any 
incompatibilities 
Eating, drinking and smoking should be prohibited in areas where this material is handled, 
stored and processed. Workers should wash hands and face before eating, drinking and 
smoking. Remove contaminated clothing and protective equipment before entering 
eating areas. See also Section 8 for additional information on hygiene measures. 
Store in accordance with local regulations. Store in original container protected from 
direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials 
(see Section 10) and food and drink. Keep container tightly closed and sealed until ready 
for use. Containers that have been opened must be carefully resealed and kept upright 
to prevent leakage. Do not store in unlabeled containers. Use appropriate containment 
to avoid environmental contamination. 
: 
: 
Protective measures : Put on appropriate personal protective equipment (see Section 8). Avoid breathing 
dust. 
Precautions for safe handling 
None. 
Section 8. Exposure controls/personal protection 
Hand protection 
Use a properly fitted, particulate filter respirator complying with an approved standard if a 
risk assessment indicates this is necessary. Respirator selection must be based on 
known or anticipated exposure levels, the hazards of the product and the safe working 
limits of the selected respirator. 
Chemical-resistant, impervious gloves complying with an approved standard should be 
worn at all times when handling chemical products if a risk assessment indicates this is 
necessary. 
Safety eyewear complying with an approved standard should be used when a risk 
assessment indicates this is necessary to avoid exposure to liquid splashes, mists, 
gases or dusts. If contact is possible, the following protection should be worn, unless the 
assessment indicates a higher degree of protection: safety glasses with side-shields. If 
operating conditions cause high dust concentrations to be produced, use dust goggles. 
Eye/face protection 
Respiratory protection : 
: 
: 
Body protection Personal protective equipment for the body should be selected based on the task being 





: Emissions from ventilation or work process equipment should be checked to ensure they 
comply with the requirements of environmental protection legislation. In some cases, 
fume scrubbers, filters or engineering modifications to the process equipment will be 
necessary to reduce emissions to acceptable levels. 
Appropriate engineering 
controls 
: Use only with adequate ventilation. If user operations generate dust, fumes, gas, vapor 
or mist, use process enclosures, local exhaust ventilation or other engineering controls to 
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keep worker exposure to airborne contaminants below any recommended or statutory 
limits. 
Wash hands, forearms and face thoroughly after handling chemical products, before 
eating, smoking and using the lavatory and at the end of the working period. Appropriate 
techniques should be used to remove potentially contaminated clothing. Wash 
contaminated clothing before reusing. Ensure that eyewash stations and safety showers 
are close to the workstation location. 
Hygiene measures : 
Control parameters 
Individual protection measures 
Occupational exposure limits 
Skin protection 
Other skin protection : Appropriate footwear and any additional skin protection measures should be selected 
based on the task being performed and the risks involved and should be approved by a 
specialist before handling this product. 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 4/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 




















Closed cup: >100°C (>212°F) 
Not available. 
4 to 6 [Conc. (% w/w): 5%] 
Viscosity Not available. 
Odor threshold Not available. 























Boiling point : Not available. 
Flammability (solid, gas) : Slightly flammable in the presence of the following materials or conditions: heat. 
Non-flammable in the presence of the following materials or conditions: shocks and 
mechanical impacts. 
May be combustible at high temperature. 
Lower and upper explosive 
(flammable) limits 
: Not available. 
Burning rate : Not available. 
Burning time : Not available. 
SADT : Not available. 
Decomposition temperature : >240°C (>464°F) 
Solubility in water : 37.22 g/l 
Section 10. Stability and reactivity 
Hazardous decomposition 
products 
Conditions to avoid No specific data. 
Under normal conditions of storage and use, hazardous decomposition products should 
not be produced. 
Chemical stability The product is stable. 




Incompatible materials : 
Possibility of hazardous 
reactions 
: Under normal conditions of storage and use, hazardous reactions will not occur. 
Reactivity : No specific test data related to reactivity available for this product or its ingredients. 
Section 11. Toxicological information 
Acute toxicity 
Information on toxicological effects 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 5/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 11. Toxicological information 
Glycine, N,N'-1, 
2-ethanediylbis[N- 
(carboxymethyl)-, sodium salt, 
hydrate (1:2:2) 
LD50 Oral Rat >2000 mg/kg - 
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Information on the likely 
routes of exposure 
Inhalation : Exposure to airborne concentrations above statutory or recommended exposure limits 
may cause irritation of the nose, throat and lungs. Exposure to decomposition products 
may cause a health hazard. Serious effects may be delayed following exposure. 
Ingestion : No known significant effects or critical hazards. 
Skin contact : No known significant effects or critical hazards. 
Exposure to airborne concentrations above statutory or recommended exposure limits 
may cause irritation of the eyes. 
Eye contact : 
Symptoms related to the physical, chemical and toxicological characteristics 
Skin contact 
Ingestion 
Inhalation Adverse symptoms may include the following: 
respiratory tract irritation 
coughing 
No specific data. 




Eye contact : Adverse symptoms may include the following: 
irritation 
redness 
Specific target organ toxicity (single exposure) 





: Routes of entry anticipated: Oral, Inhalation. 




(carboxymethyl)-, sodium salt, 
hydrate (1:2:2) 
None. - - 
Product/ingredient name OSHA IARC NTP 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 6/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 11. Toxicological information 
Not available. 
Conclusion/Summary : Exposure can cause stomach pains, vomiting and diarrhea. 
General : Repeated or prolonged inhalation of dust may lead to chronic respiratory irritation. 
Carcinogenicity : No known significant effects or critical hazards. 
Mutagenicity : No known significant effects or critical hazards. 
Teratogenicity : No known significant effects or critical hazards. 
Developmental effects : No known significant effects or critical hazards. 
Fertility effects : No known significant effects or critical hazards. 
Potential chronic health effects 
Delayed and immediate effects and also chronic effects from short and long term exposure 
Numerical measures of toxicity 
Not available. 
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: Not available. 
Short term exposure 
Potential delayed effects : Not available. 
Potential immediate 
effects 
: Not available. 
Long term exposure 
Potential delayed effects : Not available. 
Section 12. Ecological information 
Bioaccumulative potential 




Persistence and degradability 
Soil/water partition 
coefficient (KOC) 
: Not available. 
Mobility in soil 
Not available. 
Section 13. Disposal considerations 
The generation of waste should be avoided or minimized wherever possible. Disposal of 
this product, solutions and any by-products should at all times comply with the 
requirements of environmental protection and waste disposal legislation and any regional 
local authority requirements. Dispose of surplus and non-recyclable products via a 
licensed waste disposal contractor. Waste should not be disposed of untreated to the 
sewer unless fully compliant with the requirements of all authorities with jurisdiction. 
Waste packaging should be recycled. Incineration or landfill should only be considered 
when recycling is not feasible. This material and its container must be disposed of in a 
safe way. Empty containers or liners may retain some product residues. Avoid dispersal 
Disposal methods : 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 7/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 13. Disposal considerations 
of spilled material and runoff and contact with soil, waterways, drains and sewers. 


























Special precautions for user 
Transport in bulk according 
to Annex II of MARPOL 
73/78 and the IBC Code 
No. No. 
Transport within user’s premises: always transport in closed containers that are 
upright and secure. Ensure that persons transporting the product know what to do in the 
event of an accident or spillage. 
: Not available. 
: 
Section 15. Regulatory information 
U.S. Federal regulations : 
Clean Air Act Section 112 
(b) Hazardous Air 
Pollutants (HAPs) 
: Not listed 
Clean Air Act Section 602 
Class I Substances 
: Not listed 
Clean Air Act Section 602 
Class II Substances 
: Not listed 
DEA List I Chemicals 
(Precursor Chemicals) 
: Not listed 
DEA List II Chemicals 
(Essential Chemicals) 
: Not listed 
State regulations 
TSCA 8(a) CDR Exempt/Partial exemption: Not determined 
United States inventory (TSCA 8b): This material is listed or exempted. 
SARA 302/304 
SARA 304 RQ : Not applicable. 
No products were found. 
Composition/information on ingredients 
SARA 311/312 
Classification : Not applicable. 
No products were found. 
Composition/information on ingredients 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 8/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 15. Regulatory information 
Massachusetts : This material is not listed. 
New York : This material is not listed. 
New Jersey : This material is not listed. 
Pennsylvania : This material is not listed. 
Canada inventory : This material is listed or exempted. 
Australia inventory (AICS): This material is listed or exempted. 
China inventory (IECSC): This material is listed or exempted. 
Japan inventory: This material is listed or exempted. 
Korea inventory: This material is listed or exempted. 
Malaysia Inventory (EHS Register): Not determined. 
New Zealand Inventory of Chemicals (NZIoC): This material is listed or exempted. 
Philippines inventory (PICCS): This material is listed or exempted. 
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International lists : 
Chemical Weapons 
Convention List Schedule I 
Chemicals 
: Not listed 
Chemical Weapons 
Convention List Schedule 
II Chemicals 
: Not listed 
Chemical Weapons 
Convention List Schedule 
III Chemicals 
: Not listed 
Section 16. Other information 
12/12/2013. 
History 
Date of printing : 
: 8/23/2013. 














Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, 
and 4 
representing significant hazards or risks Although HMIS® ratings are not required on SDSs under 29 
CFR 1910. 
1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented 
HMIS® 
program. HMIS® is a registered mark of the National Paint & Coatings Association (NPCA). HMIS® 
materials may 
be purchased exclusively from J. J. Keller (800) 327-6868. 
The customer is responsible for determining the PPE code for this material. 
Reprinted with permission from NFPA 704-2001, Identification of the Hazards of Materials for 
Emergency 
Response Copyright ©1997, National Fire Protection Association, Quincy, MA 02269. This reprinted 
material is 
not the complete and official position of the National Fire Protection Association, on the referenced 
subject 
which is represented only by the standard in its entirety. 
Copyright ©2001, National Fire Protection Association, Quincy, MA 02269. This warning system is 
intended to be 
interpreted and applied only by properly trained individuals to identify fire, health and reactivity 
hazards of 
chemicals. The user is referred to certain limited number of chemicals with recommended 
classifications in NFPA 
49 and NFPA 325, which would be used as a guideline only. Whether the chemicals are classified by 
NFPA or not, 
anyone using the 704 systems to classify chemicals does so at their own risk. 
 
 




Chronic Health Hazard 
Date of issue/Date of revision : 8/23/2013. Date of previous issue : No previous validation. Version : 1 9/10 
Ethylenediamine Tetraacetic Acid, Disodium Salt 
Section 16. Other information 
Date of issue/Date of 
revision 
Version 
To the best of our knowledge, the information contained herein is accurate. However, neither the 
above-named 
supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or 
completeness of the 
information contained herein. 
Final determination of suitability of any material is the sole responsibility of the user. All materials may 
present 
unknown hazards and should be used with caution. Although certain hazards are described herein, we 
cannot 
guarantee that these are the only hazards that exist. 
Notice to reader 
Date of previous issue 
: 
: 
Indicates information that has changed from previously issued version. 
References : Not available. 
Key to abbreviations : ATE = Acute Toxicity Estimate 
BCF = Bioconcentration Factor 
GHS = Globally Harmonized System of Classification and Labelling of Chemicals 
IATA = International Air Transport Association 
IBC = Intermediate Bulk Container 
IMDG = International Maritime Dangerous Goods 
LogPow = logarithm of the octanol/water partition coefficient 
MARPOL 73/78 = International Convention for the Prevention of Pollution From Ships, 
1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) 
UN = United Nations 
No previous validation. 
1 
Prepared by : SDS Specialist 






































MATERIAL SAFETY DATA SHEET - “LIQUID NITROGEN” 
ROC Group of Companies Page 1 of 6 
1. PRODUCT AND COMPANY IDENTIFICATION 
PRODUCT NAME: Nitrogen, refrigerated liquid 
CHEMICAL NAME: Nitrogen 
CHEMICAL FAMILY: Inert gas 
SYNONYMS: Cryogenic Liquid Nitrogen, Liquid Nitrogen, LIN 
CHEMICAL FORMULA: N2 
USE: Medical purposes, Inerting, Safe storage of Food, Concrete strengthening, 
etc., 
NAME AND ADDRESS: Refrigeration & Oxygen Co. 
Corporate Office 
Area No 1, Block 21 C, 
Central Slaughter House Street 
Shuwaikh Industrial Area 
Kuwait. 
WEB ADDRESS: www.rockuwait.com; E-mail: info@rocq8.com 
TELEPHONE: (+965) 844 844 
2. HAZARDS IDENTIFICATION 
EMERGENCY OVERVIEW: 
WARNING! Extremely cold liquid and gas under pressure. 
Can cause rapid suffocation. 
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Can cause severe frostbite. 
POTENTIAL HEALTH EFFECTS INFORMATION: 
ROUTES OF EXPOSURE: 
INHALATION: Simple Asphyxiant. 
Nontoxic, but may cause suffocation by displacing the oxygen in air. Exposure to oxygen-
deficient 
atmosphere (<19.5%) may cause dizziness, drowsiness, nausea, vomiting, excess salivation, 
diminished mental alertness, loss of consciousness and death. Exposure to atmospheres 
containing 
8% to 10% or less oxygen will bring about unconsciousness without warning and so quickly that 
the individuals cannot help or protect themselves. Lack of sufficient oxygen may cause serious 
injury or death. 
EYE CONTACT: Tissue freezing and severe cryogenic burns of eyes 
SKIN CONTACT: Tissue freezing and severe cryogenic burns of skin 
SKIN ABSORPTION: Not applicable 
INGESTION: Not applicable 
CHRONIC EFFECTS: None established 
MEDICAL CONDITIONS AGGRAVATED BY OVEREXPOSURE: None 
OTHER EFFECTS OF OVEREXPOSURE: None 
CARCINOGENICITY: Not listed by NTP, OSHA, or IARC. 
POTENTIAL ENVIRONMENTAL EFFECTS: No adverse ecological effects are expected. 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
MATERIAL SAFETY DATA SHEET - “LIQUID NITROGEN” 
ROC Group of Companies Page 2 of 6 
INGREDIENT NAME: Nitrogen 
PERCENTAGE >99% 
CAS NUMBER 7727-37-9 
4. FIRST AID MEASURES 
FIRST AID PROCEDURES: 
INHALATION: Persons suffering from lack of oxygen should be removed to fresh air. If victim 
is 
not breathing, give artificial respiration. If breathing is difficult, give oxygen. Obtain prompt 
medical attention. 
EYE CONTACT: In case of splash contamination, immediately flush eyes with water for at least 
15 minutes. See a physician, preferably an ophthalmologist. 
SKIN CONTACT: Remove any clothing that may restrict circulation to frozen area. Do not rub 
frozen parts as tissue damage may result. As soon as practical, place the affected area in a warm 
water bath which has a temperature not exceeding 105 °F (40°C). Never use dry heat. In case of 
massive exposure, remove clothing while showering with warm water. Call a physician as soon 
as 
possible. 
Frozen tissue is painless and appears waxy with a possible yellow color. It will become swollen, 
painful, and prone to infection when thawed. If the frozen part of the body has been thawed by 
the 
time medical attention has been obtained, cover the area with dry sterile dressing with a large 
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bulky protective covering. 
INGESTION: Not applicable 
NOTES TO PHYSICIAN: None 
5. FIREFIGHTING MEASURES 
FLAMMABLE PROPERTIES: Nonflammable and does not support combustion. 
EXTINGUISHING MEDIA: Use extinguishing media appropriate for the surrounding fire. 
PROTECTION OF FIREFIGHTERS: 
SPECIFIC HAZARDS ARISING FROM THE CHEMICAL: When spilled the liquid will 
vaporize 
rapidly forming an oxygen-deficient vapor cloud. Evacuate this vapor cloud area. Visibility may 
be 
obscured in the vapor cloud. Pressure in a container can build up due to heat and it may rupture if 
pressure relief devices should fail to function. Contact with cold liquid or gas may cause 
frostbite. 
PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIREFIGHTERS: Simple 
asphyxiant. 
If possible, remove containers from fire area or cool with water. Do not direct water spray at the 
container vent. Self contained breathing apparatus may be required for rescue workers. Evacuate 
this area. 
SENSITIVITY TO STATIC DISCHARGE: Not Applicable 
SENSITIVITY TO MECHANICAL IMPACT: None 
6. ACCIDENTAL RELEASE MEASURES 
MATERIAL SAFETY DATA SHEET - “LIQUID NITROGEN” 
ROC Group of Companies Page 3 of 6 
PERSONAL PRECAUTIONS: Use personal protection recommended in Section 8. Evacuate all 
personnel from the affected area. Ventilate area or remove containers to a well ventilated 
location. 
To increase rate of vaporization, spray large amounts of water onto the spill from an upwind 
position. If leaking from container or its valve, contact your supplier. 
ENVIRONMENTAL PRECAUTIONS: Not applicable. 
METHODS FOR CONTAINMENT: Shut off source if possible without risk. 
METHODS FOR CLEAN-UP: Not applicable. 
OTHER INFORMATION: None. 
7. HANDLING AND STORAGE 
HANDLING: Never allow any unprotected part of the body to touch un-insulated pipes or 
vessels 
that contain cryogenic fluids. The extremely cold metal will cause the flesh to stick fast and tear 
when one attempts to withdraw from it. 
Use a suitable four-wheel hand truck for container movement. Cryogenic containers shall be 
handled and stored in an upright position. Do not drop or roll containers on their sides. If user 
experiences any difficulty operating container valve discontinue use and contact supplier. For 
additional precautions see Section 16, Other Information. 
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from materials and conditions that present exposure hazards to or from each other. Do not store 
in 
a confined space. Cryogenic containers are equipped with pressure relief devices to control 
internal 
pressure. Under normal conditions these containers will periodically vent product. Some metals 
such as carbon steel may become brittle at low temperatures and will easily fracture. Prevent 
entrapment of liquid in closed systems or piping without pressure relief. 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
EXPOSURE GUIDELINES: 
OSHA PEL-TWA: None NIOSH IDLH: None 
ACGIH TLV: Simple asphyxiant 
ENGINEERING CONTROLS: 
VENTILATION: Natural or mechanical to prevent oxygen-deficient atmospheres below 19.5% 
oxygen. 
PERSONAL PROTECTIVE EQUIPMENT: 
EYE/FACE PROTECTION: Full face shield and safety glasses are recommended. 
SKIN PROTECTION: Loose fitting thermal insulated or leather gloves. Safety shoes are 
recommended when handling liquid containers. Long sleeve shirts and trousers without cuffs. 
RESPIRATORY PROTECTION (SPECIFY TYPE): 
General Use: None required 
Emergency Use: Self-contained breathing apparatus (SCBA) or positive pressure airline with 
mask 
are to be used in oxygen-deficient atmosphere. Air purifying respirators will not function. 
9. PHYSICAL AND CHEMICAL PROPERTIES 
MATERIAL SAFETY DATA SHEET - “LIQUID NITROGEN” 
ROC Group of Companies Page 4 of 6 
APPEARANCE: Colorless 
ODOR: Odorless 
ODOR THRESHOLD: Not applicable 
PHYSICAL STATE: Cryogenic liquid 
pH: Not applicable 
MELTING POINT: -345.8 ºF (-209.9 ºC) @ 1 atm 
BOILING POINT: -320.4 ºF (-195.8 ºC) @ 1 atm 
FLASH POINT: Not applicable 
EVAPORATION RATE (Butyl Acetate=1): Not applicable 
FLAMMABILITY: Nonflammable 
FLAMMABLE LIMITS IN AIR BY VOLUME: 
LOWER: Not applicable; UPPER: Not applicable 
VAPOR PRESSURE (AT 20 °C): Not applicable 
GAS DENSITY: 0.072 lb/ft3 (1.153 kg/m3) @ 70 of (21.1 °C) and 1 atm 
SPECIFIC GRAVITY (Air =1): 0.967 @ 70 °F (21.1 °C) and 1 atm 
SOLUBILITY IN WATER: Vol/Vol at 32 °F (0 °C): 0.023 
COEFFICIENT OF WATER/OIL DISTRIBUTION: Not available 
AUTOIGNITION: Nonflammable 
DECOMPOSITION TEMPERATURE: Not applicable 
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MOLECULAR WEIGHT: 28.01 
EXPANSION RATIO: (for liquid to gas) 70 °F (21.1 °C): 1 to 696.5 
10. STABILITY AND REACTIVITY 
CHEMICAL STABILITY: Stable 
CONDITIONS TO AVOID: None 
INCOMPATIBLE MATERIALS: None 
HAZARDOUS DECOMPOSITION PRODUCTS: None 
POSSIBILITY OF HAZARDOUS REACTIONS: Will not occur 
11. TOXICOLOGICAL INFORMATION 
The product is simple asphyxiant. 
ACUTE DOSE EFFECTS: LD50: None LCso: None 
REPEATED DOSE EFFECTS: None established 
IRRITATION: None 
SENSITIZATION: None 
GENETIC EFFECTS: None 
DEVELOPMENTAL EFFECTS: None 
TERATOGENICITY: None 
SYNERGISTIC MATERIALS: None 
REPRODUCTIVE EFFECTS: None 
TARGET ORGAN EFFECTS: None 
MATERIAL SAFETY DATA SHEET - “LIQUID NITROGEN” 
ROC Group of Companies Page 5 of 6 
MUTAGENICITY: None 
12. ECOLOGICAL INFORMATION 
ECOTOXICITY: No adverse ecological effects are expected. It does not contain any Class I or 
Class II ozone depleting chemicals (40 CFR Part 82). Not listed as a marine pollutant by DOT 
(49 
CFR Part 171). 
13. DISPOSAL CONSIDERATIONS 
WASTE DISPOSAL METHOD: Do not attempt to dispose of residual or unused quantities. 
Contact your supplier. 
For emergency disposal, discharge slowly to the atmosphere in a well ventilated area or 
outdoors. 
14. TRANSPORT INFORMATION 
Product Identification Number: 1977 
BASIC SHIPPING DESCRIPTION: 
PROPER SHIPPING NAME: Nitrogen, refrigerated liquid 
HAZARD CLASS: 2.2 (Nonflammable Gas) 
IDENTIFICATION NUMBER: UN 1977 
ADDITIONAL INFORMATION: 
PRODUCT RQ: Not applicable 
SHIPPING LABEL(s): Nonflammable gas 
PLACARD (When required): Nonflammable gas 
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well ventilated vehicle. The transportation of compressed gas containers in automobiles or in 
closed-body vehicles can present serious safety hazards and should be discouraged. For air 
shipments, the "Cryogenic Liquid" handling label must be used in addition to the nonflammable 
gas (Division 2.2) hazard label on packages and over packs containing cryogenic liquids. 
15. REGULATORY INFORMATION & OTHER INFORMATION 
SPECIAL PRECAUTIONS: Use piping and equipment adequately designed to withstand 
pressures and temperatures to be encountered. Use a check valve or other protective apparatus in 
any line or piping from the container to prevent reverse flow. Cross contamination of gases, 
liquids, or both can also create a hazardous condition inside a cylinder, dewar, or vessel (e.g., 
flammable and oxidizing gases can create an explosive mixture), which may result in rupture. To 
prevent cryogenic liquids or cold gas from being trapped in piping between valves the piping 
shall 
be equipped with pressure relief devices. Only transfer lines designed for cryogenic liquids shall 
be 
used. It is recommended that all vents be piped to the exterior of the building. 
Shipment of compressed gas containers that have not been filled with the owner's consent is a 
violation of Federal law (49 CFR Part 173.301.b) 
HAZARD RATINGS AND RATING SYSTEMS: 
NFPA RATINGS: 
MATERIAL SAFETY DATA SHEET - “LIQUID NITROGEN” 
ROC Group of Companies Page 6 of 6 
HEALTH: =3; FLAMMABILITY: =0; INSTABILITY: =0; SPECIAL: SA 
STANDARD VALVE CONNECTIONS: 
THREADED: CGA 295 
PIN-INDEXED YOKE: Not applicable 
ULTRA HIGH INTEGRITY: Not applicable 
Use the proper connections; DO NOT USE ADAPTERS. DO NOT FORCE FIT 
CONNECTIONS. 
The information and recommendations in this Material Safety Data 
Sheet relate only to the specific material mentioned herein and 
do 
not relate to use otherwise ie., in combination with any other 
material or in any process. 
The information and recommendations herein are taken from our 
extensive experiences and the data contained in recognized 
references and believed by us to be accurate. Refrigeration 
group 
of companies make no warranties either expressed or implied with 
respect there to and assume no liability in connection with the 











Safety Data Sheet 
SECTION 2: Hazards identification 
Health hazards 
GHS - Classification 
Skin corrosion/irritation Category 2 
Serious eye damage/eye irritation Category 2 
Respiratory sensitization Category 1 
Specific target organ systemic toxicity (single exposure) Category 3 
Signal Word 
DANGER 
Identification of the substance or mixture 
_________________________________________________________________________________________________________
_______ 
24 hour Emergency Response: 866-536-0631 
301-431-8585 






For research use only. Not intended for human or animal diagnostic or therapeutic uses. 
Revision date 
Product name TRYPSIN, 1/250Trypsin (1:250) porcine parvovirus 
tested 
Not Hazardous 
Page 1 / 6 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
Product name 
30-Jan-2015 




5250 Mainway Drive 
Burlington, ONT 
CANADA L7L 6A4 
800/263-6236 
Life Technologies 
5791 Van Allen Way 
PO Box 6482 
Carlsbad, CA 92008 
+1 760 603 7200 
Reproductive toxicity None 
Skin 
Sensitization R42 - May cause sensitization by inhalation 
Irritating to skin. 
Target Organ Effects None under normal use conditions 
inhalation Irritating to respiratory system. 
SECTION 4: First aid measures 
Ingestion 
Skin contact Wash off immediately with plenty of water for at least 15 minutes. Take off all 








May be harmful if swallowed. Ingestion may cause gastrointestinal irritation, 
nausea, vomiting and diarrhea. 
Hazard Statements 
H316 - Causes mild skin irritation 
H320 - Causes eye irritation 
H335 - May cause respiratory irritation 
H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled 
Precautionary Statements 
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray 
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if 
present and easy to do. Continue rinsing 
P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician 
P332 + P313 - If skin irritation occurs: Get medical advice/attention 
P304 + P312 - IF INHALED: Call a POISON CENTER or doctor if you feel unwell 
P312 - Call a POISON CENTER or doctor/physician if you feel unwell 
Principle Routes of Exposure 
Potential Health Effects 
Specific effects 
Carcinogenic effects None 
eyes Irritating to eyes. 
Mutagenic effects None 
_________________________________________________________________________________________________________
_______ 
SECTION 3: Composition/information on ingredients 
Flammability 0 
Health 2 * Chronic Hazard 
27250018 
Chemical Name CAS-No 
Revision date 
EINECS-No 
Product name TRYPSIN, 1/250Trypsin (1:250) porcine parvovirus 
tested 
Weight % 







We recommend handling all chemicals with caution. 
Engineering measures Ensure adequate ventilation, especially in confined areas. 
Ingestion Call a physician or poison control center immediately. Never give anything by 
mouth to an unconscious person. Do not induce vomiting without medical advice. 
See Section 12 for more information. 
SECTION 6: Accidental release measures 
Personal Protective Equipment 
Personal Protective Equipment requirements are dependent on the user institution's risk assessment and 
are specific 
to the risk assessment for each laboratory where this material may be used. 
Notes to Physician 
SECTION 7: Handling and storage 
Treat symptomatically. 
Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment. 
Suitable extinguishing media 
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Personal precautions Ensure adequate ventilation. Avoid contact with skin, eyes or clothing. Use 
personal protection equipment. 
Handling Always wear reccommended Personal Protective Equipment. No special handling 
advices are necessary. 
Hand protection Impervious gloves. 
Water spray. Carbon dioxide (CO2). Foam. Dry chemical. 
Eye contact 
Eye protection Wear safety glasses with side shields (or goggles). 
Storage Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers. 
Skin and Body Protection Lightweight protective clothing. 
Methods for cleaning up Take up mechanically, placing in appropriate containers for disposal. 
Hygiene measures Handle in accordance with good industrial hygiene and safety practice. 
Rinse immediately with plenty of water, also under the eyelids, for at least 15 
minutes. Immediate medical attention is required. 
Special protective equipment for firefighters 
SECTION 8: Exposure controls/personal protection 
_________________________________________________________________________________________________________
_______ 






Chemical Name OSHA PEL 
Revision date 
OSHA PEL (Ceiling) 
Product name TRYPSIN, 1/250Trypsin (1:250) porcine parvovirus 
tested 
ACGIH OEL (TWA) 
Page 3 / 6 
ACGIH OEL (STEL) 
Remove to fresh air. If not breathing, give artificial respiration. Call a physician or 







Prevent further leakage or spillage if safe to do so. Prevent product from entering drains. 
SECTION 5: Firefighting measures 
Principle Routes of Exposure 
Potential Health Effects 
eyes Irritating to eyes 
SECTION 9: Physical and chemical properties 
Skin Irritating to skin 
SECTION 10: Stability and reactivity 
inhalation Irritating to respiratory system 
Ingestion May be harmful if swallowed Ingestion may cause gastrointestinal irritation, 
nausea, vomiting and diarrhea 
Environmental exposure 
controls 
Carcinogenic effects None 
Stability Stable under normal conditions. 
Mutagenic effects None 
Prevent product from entering drains. Do not allow material to contaminate ground 
 
 




Reproductive toxicity None. 
Materials to avoid Strong oxidizing agents. 




None under normal use conditions. 
Target Organ Effects None under normal use conditions 
solid 
polymerization None under normal processing. 
SECTION 12: Ecological information 
Appearance 
SECTION 11: Toxicological information 








Chemical Name LD50 (oral,rat/mouse) LD50 (dermal,rat/rabbit) LC50 (inhalation,rat/mouse) 
Water solubility soluble 
Trypsin No data available No data available 
27250018 
No data available 
No information available 
Revision date 
°F No data available 
Product name TRYPSIN, 1/250Trypsin (1:250) porcine parvovirus 
tested 
°C No data available 
Page 4 / 6 
°F No data available 
°F No data available 
Melting point / melting range °C No data available 
30-Jan-2015 
Autoignition Temperature 
°C No data available 
www.lifetechnologies.com 
Boiling point / boiling range °F No data available 
Product code 
flash point 
°C No data available 
SECTION 13: Disposal considerations 
Mobility 
IATA 
No information available 
Proper shipping name No dangerous good in sense of these transport regulations 
Dispose of contents/containers in accordance with local regulations. 
Hazard Class None 
Bioaccumulation 
Subsidiary class None 
No information available 
Packing group None 
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SECTION 14: Transport information 
UN-No none 
Biodegradation No information available 
SECTION 15: Regulatory information 
Trypsin 
9002-07-7 ( 60-100 ) 
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) 
and the 
MSDS contains all the information required by the CPR. 
US State Regulations 
Listed 
SARA 313 
This product is not regulated by SARA. 
Component 
Chemical Name Massachusetts - RTK New Jersey - RTK Pennsylvania - RTK 
_________________________________________________________________________________________________________
_______ 
Illinois - RTK Rhode Island - RTK 
Trypsin - Listed - - - 
27250018 
Revision date 
Product name TRYPSIN, 1/250Trypsin (1:250) porcine parvovirus 
tested 
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TSCA 
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61) 
This product does not contains HAPs. 
California Proposition 65 
This product does not contain any Proposition 65 chemicals. 
30-Jan-2015 
US Federal Regulations 
www.lifetechnologies.com 
Product code 
WHMIS Hazard Class 
D2A - Very toxic materials 
D2B - Toxic materials 
"The above information was acquired by diligent search and/or investigation and the recommendations 
are based on 
prudent application of professional judgment. The information shall not be taken as being all inclusive and 
is to be 
used only as a guide. All materials and mixtures may present unknown hazards and should be used with 
caution. 
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall 
not be held 
liable for any damages or losses resulting from the handling or from contact with the product as described 
herein. 
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR 
IMPLIED, 




For research use only. Not intended for human or animal diagnostic or therapeutic uses. 
Product name TRYPSIN, 1/250Trypsin (1:250) porcine parvovirus 
tested 
End of Safety Data Sheet 
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SECTION 16: Other information 
Reason for revision 
 
 






SDS sections updated. 
27250018 
Revision date 
 
